

1. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. *Endocr Rev.* 1998; 19: 717–797.
2. Veldhuis JD. A tripeptidyl ensemble perspective of interactive control of growth hormone secretion. *Horm Res.* 2003; 60 (Suppl 1): 86–101.
3. Sutton J, Lazarus L. Growth hormone in exercise: comparison of physiological and pharmacological stimuli. *J Appl Physiol.* 1976; 41: 523–527.
4. Christensen SE, Jørgensen OL, Møller N, Orskov H. Characterization of growth hormone release in response to external heating. Comparison to exercise induced release. *Acta Endocrinol (Copenh).* 1984; 107: 295–301.
5. Felsing NE, Brasel JA, Cooper DM. Effect of low and high intensity exercise on circulating growth hormone in men. *J Clin Endocrinol Metab.* 1992; 75: 157–162.
6. Elias AN, Wilson AF, Naqvi S, Pandian MR. Effects of blood pH and blood lactate on growth hormone, prolactin, and gonadotropin release after acute exercise in male volunteers. *Proc Soc Exp Biol Med.* 1997; 214: 156–160.
7. Wheldon A, Savine RL, Sönksen PH, Holt RI. Exercising in the cold inhibits growth hormone secretion by reducing the rise in core body temperature. *Growth Horm IGF Res.* 2006; 16: 125–131.
8. Nass R, Huber RM, Klauss V, Müller OA, Schopohl J, Strasburger CJ. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. *J Clin Endocrinol Metab.* 1995; 80: 552–557.
9. Whitehead HM, Boreman C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. *Clin Endocrinol (Oxf).* 1992; 36: 45–52.
10. Beshyah SA, Freemantle C, Shahi M, Anyaoku V, Merson S, Lynch S, Skinner E, Sharp P, Foale R, Johnston DG. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. *Clin Endocrinol (Oxf).* 1995; 42: 73–84.
11. Degerblad M, Almkvist O, Grunditz R, Hall K, Kaijser L, Knutsson E, Ringertz H, Thorén M. Physical and psychological capabilities during substitution therapy with recombinant growth hormone in adults with growth hormone deficiency. *Acta Endocrinol (Copenh).* 1990; 123: 185–193.
12. Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. *J Clin Endocrinol Metab.* 2008; 93: 4413–4417.
13. Golde DW, Bersch N, Li CH. Growth hormone: species-specific stimulation of erythropoiesis in vitro. *Science.* 1977; 196: 1112–1113.
14. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. *Endocr Rev.* 1994; 15: 555–573.
15. Johannsson G, Sverrisdóttir YB, Ellegård L, Lundberg PA, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. *J Clin Endocrinol Metab.* 2002; 87: 1743–1749.
16. Janssen YJ, Doornbos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. *J Clin Endocrinol Metab.* 1999; 84: 279–284.
17. Hunter WM, Fonseka CC, Passmore R. The role of growth hormone in the mobilization of fuel for muscular exercise. *Q J Exp Physiol Cogn Med Sci.* 1965; 50: 406–416.
18. Wee J, Charlton C, Simpson H, Jackson NC, Shojaee-Moradie F, Stolinski M, Pentecost C, Umpleby AM. GH secretion in acute exercise may result in post-exercise lipolysis. *Growth Horm IGF Res.* 2005; 15: 397–404.
19. Lassarre C, Girard F, Durand J, Raynaud J. Kinetics of human growth hormone during submaximal exercise. *J Appl Physiol.* 1974; 37: 826–830.
20. Pritzlaff-Roy CJ, Widemen L, Weltman JY, Abbott R, Gutgesell M, Hartman ML, Veldhuis JD, Weltman A. Gender governs the relationship between exercise intensity and growth hormone release in young adults. *J Appl Physiol.* 2002; 92: 2053–2060.
21. Wideman L, Consitt L, Patrie J, Swearingin B, Bloomer R, Davis P, Weltman A. The impact of sex and exercise duration on growth hormone secretion. *J Appl Physiol.* 2006; 101: 1641–1647.
22. Kanaley JA, Weltman JY, Veldhuis JD, Rogol AD, Hartman ML, Weltman A. Human growth hormone response to repeated bouts of aerobic exercise. *J Appl Physiol.* 1997; 83: 1756–1761.
23. Kanaley JA, Weltman JY, Pieper KS, Weltman A, Hartman ML. Cortisol and growth hormone responses to exercise at different times of day. *J Clin Endocrinol Metab.* 2001; 86: 2881–2889.
24. Gilbert KL, Stokes KA, Hall GM, Thompson D. Growth hormone responses to 3 different exercise bouts in 18- to 25- and 40- to 50-year-old men. *J Appl Physiol Nutr Metab.* 2008; 33: 706–712.
25. Wideman L, Weltman JY, Shah N, Story S, Veldhuis JD, Weltman A. Effects of gender on exercise-induced growth hormone release. *J Appl Physiol.* 1999; 87: 1154–1162.
26. Zaccaria M, Varnier M, Piazza P, Noventa D, Ermolao A. Blunted growth hormone response to maximal exercise in middle aged versus young subjects and no effect of endurance training. *J Clin Endocrinol Metab.* 1999; 84: 2303–2307.
27. Veldhuis JD, Liem AY, South S, Weltman A, Weltman J, Clemmons DA, Abbott R, Mulligan T, Johnson ML, Pincus S. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. *J Clin Endocrinol Metab.* 1995; 80: 3209–3222.
28. Prange Hansen A. Serum growth hormone response to exercise in non-obese and obese normal subjects. *Scand J Clin Lab Invest.*

- 1973; 31: 175–178.
29. Scacchi M, Valassi E, Ascoli P, Cavagnini F. Obesity, hyponutrition and growth hormone. *Obes Metab.* 2007; 3: 68–87.
 30. Holt RI, Webb E, Pentecost C, Sönksen PH. Aging and physical fitness are more important than obesity in determining exercise-induced generation of GH. *J Clin Endocrinol Metab.* 2001; 86: 5715–5720.
 31. Bang P, Brandt J, Degerblad M, Enberg G, Kaijser L, Thorén M, Hall K. Exercise-induced changes in insulin-like growth factors and their low molecular weight binding protein in healthy subjects and patients with growth hormone deficiency. *Eur J Clin Invest.* 1990; 20: 285–292.
 32. Schwarz AJ, Brasel JA, Hintz RL, Mohan S, Cooper DM. Acute effect of brief low- and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. *J Clin Endocrinol Metab.* 1996; 81: 3492–3497.
 33. Wallace JD, Cuneo RC, Baxter R, Orskov H, Keay N, Pentecost C, Dall R, Rosén T, Jørgensen JO, Cittadini A, Longobardi S, Sacca L, Christiansen JS, Bengtsson BA, Sönksen PH. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. *J Clin Endocrinol Metab.* 1999; 84: 3591–3601.
 34. Healy ML, Gibney J, Pentecost C, Croos P, Russell-Jones DL, Sönksen PH, Umpleby AM. Effects of high-dose growth hormone on glucose and glycerol metabolism at rest and during exercise in endurance-trained athletes. *J Clin Endocrinol Metab.* 2006; 91: 320–327.
 35. Berggren A, Ehrnborg C, Rosén T, Ellegård L, Bengtsson BA, Caidahl K. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. *J Clin Endocrinol Metab.* 2005; 90: 3268–3273.
 36. Nagulesparen M, Trickey R, Davies MJ, Jenkins JS. Muscle changes in acromegaly. *Br Med J.* 1976; 16: 914–915.
 37. Gibney J, Healy ML, Sönksen PH. The growth hormone/insulin-like growth factor-I axis in exercise and sport. *Endocr Rev.* 2007; 28: 603–624.
-
1. Sapolsky RM, Romero M, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. *Endocr Rev.* 2000; 21:55–89.
 2. Smoak B, Deuster PA, Rabin D, Chrousos GP. Corticotropin-releasing hormone is not the sole factor mediating exercise-induced adrenocorticotropin release in humans. *J Clin Endocrinol Metab.* 1991; 73:302–306.
 3. Duclos M, Guinot M, Le Bouc Y. Cortisol and GH: odd and controversial ideas. *Appl Physiol Nutr Metab.* 2007; 32(5):895–903.
 4. Duclos M, Corcuff JB, Rashedi M, et al. Trained versus untrained men: different immediate post-exercise responses of pituitary-adrenal axis. *Eur J Appl Physiol.* 1997; 75:343–350.
 5. Luger A, Deuster PA, Kyle SB, et al. Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. *New Engl J Med.* 1987; 316:1309–1315.
 6. Kjaer M, Secher NH, Bach FW, Galbo H. Role of motor center activity for hormonal changes and substrate mobilization in humans. *Am J Physiol.* 1987; 253:R687–R695.
 7. Duclos M, Minkhar M, Sarrieau A, et al. Reversibility of endurance training-induced changes on glucocorticoid sensitivity of monocytes by an acute exercise. *Clin Endocrinol.* 1999; 51:749–756.
 8. Duclos M, Gouarne C, Bonnemaïson D. Acute and chronic effects of exercise on tissue sensitivity to glucocorticoids. *J Appl Physiol.* 2003; 94:869–875.
 9. Gouarne C, Groussard C, Duclos M. Overnight urinary cortisol and cortisone add new insights into adaptation to training. *Med Sci Sports Exerc.* 2005; 37(7):1157–1167.
 10. Judelson DA, Maresh CM, Yamamoto LM, et al. Effect of hydration state on resistance exercise-induced endocrine markers of anabolism, catabolism, and metabolism. *J Appl Physiol.* 2008; 105(3):816–824.
 11. Brandenberger G, Follenius M, Hietter B, et al. Feedback from meal-related peaks determines diurnal changes in cortisol response to exercise. *J Clin Endocrinol Metab.* 1982; 54:592–594.
 12. Kanaley JA, Weltman JY, Pieper KS, et al. Cortisol and growth hormone responses to exercise at different times of day. *J Clin Endocrinol Metab.* 2001; 86:2881–2889.
 13. Thuma JR, Gilders R, Verdun M, Loucks AB. Circadian rhythm of cortisol confounds cortisol responses to exercise: implications for future research. *J Appl Physiol.* 1995; 78:1657–1664.
 14. Ronsen O, Kjeldsen-Kragh J, Haug E, et al. Recovery time affects immunoendocrine responses to a second bout of endurance exercise. *Am J Physiol.* 2002; 283:C1612–C1620.
 15. Kern W, Perras B, Wodick R, et al. Hormonal secretion during nighttime sleep indicating stress of daytime exercise. *J Appl Physiol.* 1995; 79:1461–1468.
 16. Nindl BC, Friedl KE, Frykman PN, et al. Physical performance and metabolic recovery among lean, healthy men following a prolonged energy deficit. *Int J Sports Med.* 1997; 18:317–324.

17. Villanueva AL, Schlosser C, Hopper B, et al. Increased cortisol production in women runners. *J Clin Endocrinol Metab.* 1986; 63(1):133–136.
18. De Souza MJ, Van Heest J, Demers LM, Lasley BL. Luteal phase deficiency in recreational runners: evidence for a hypometabolic state. *J Clin Endocrinol Metab.* 2003; 88:337–346.
19. Loucks AB, Thuma JR. Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. *J Clin Endocrinol Metab.* 2003; 88:297–311.
20. Duclos M, Corcuff JB, Pehourcq F, Tabarin A. Decreased pituitary sensitivity to glucocorticoids in endurance trained men. *Eur J Endocrinol.* 2001; 144:363–368.
21. Droste SK, Gesing A, Ulbricht S, et al. Effects of long-term voluntary exercise on the mouse hypothalamic-pituitary-adrenocortical axis. *Endocrinology.* 2003; 144(7):3012–3023.
22. Ebrecht M, Buske-Kirschbaum A, Hellhammer D, et al. Tissue specificity of glucocorticoid sensitivity in healthy adults. *J Clin Endocrinol Metab.* 2000; 85(10):3733–3739.
23. Duclos M, Corcuff JB, Arsac L, et al. Corticotroph axis sensitivity after exercise in endurance trained athletes. *Clin Endocrinol.* 1998; 48:493–501.
24. Seckl JR, Walker BR. Minireview: 11 β -hydroxysteroid dehydrogenase type 1 – a tissue specific amplifier of glucocorticoid action. *Endocrinology.* 2001; 142:1371–1376.
25. Best R, Walker BR. Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11 β -hydroxysteroid dehydrogenase in vivo. *Clin Endocrinol (Oxf).* 1997; 47(2):231–236.
26. Atlaoui D, Duclos M, Gouarne C, et al. The 24-h urinary cortisol/cortisone ratio for monitoring training in elite swimmers. *Med Sci Sports Exerc.* 2004; 36:218–224.

1. Griffin JE. The thyroid. In: Griffin JE & Odjeda SR (eds). *Textbook of Endocrine Physiology*, 3rd Edition. Oxford University: New York, pp. 260–283, 1996.
2. Mazzaferri EL. The thyroid. In: Mazzaferri, EL (ed). *Endocrinology*, 3rd Edition. Medical Examination Publishing Co.: New York, pp. 89–350, 1985.
3. McMurray RG & AC Hackney. The endocrine system and exercise. In: Garrett W, Kirkendahl D (eds). *Exercise & Sports Science*. Williams & Wilkins Publisher: New York, pp. 135–162, 2000.
4. McMurray RG & AC Hackney. Interactions of metabolic hormones, adipose tissue and exercise. *Sports Med.* 35(5): 393–412, 2005.
5. Galbo H. The hormonal response to exercise. *Diabetes Metab Rev.* 1(4): 385–408, 1986.
6. McMurray RG, TE Eubanks & AC Hackney. Nocturnal hormonal responses to weight training exercise. *Eur J Appl Physiol.* 72: 121–126, 1995.
7. Hackney AC & A Viru. Research methodology: issues with endocrinological measurements in exercise science and sport medicine. *J Athletic Training.* 43(6): 631–639, 2008.
8. Berchtold P, M Berger & HJ Uppers. Non-glucoregulatory hormones (T4, T3, rT3 and testosterone) during physical exercise in juvenile type diabetes. *Horm Metab Res.* 10: 269–273, 1978.
9. Moore AW, S Timmerman, KK Brownlee, DA Rubin & AC Hackney. Strenuous, fatiguing exercise: relationship of cortisol to circulating thyroid hormones. *Int J Endocrinol Metab.* 1: 18–24, 2005.
10. Hackney AC & TP Gullledge. Thyroid responses during an 8 hour period following aerobic and anaerobic exercise. *Physiol Res.* 43: 1–5, 1994.
11. Opstad K. Circadian rhythm of hormones is extinguished during prolonged physical stress, sleep and energy deficiency in young men. *Eur J Endocrinol.* 131(1): 56–66, 1994.
12. Irvine CHG. Effects of exercise on thyroxine degradation in athletes and non-athletes. *J Clin Endocr.* 28: 942–948, 1968.
13. Baylor LS & AC Hackney. Resting thyroid and leptin hormone changes in women following intense, prolonged exercise training. *Eur J Appl Physiol.* 88(4–5): 480–484, 2003.
14. Douyon L & DE Schteingart. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. *Endocrinol Metab Clin North Am.* 31(1): 173–189, 2002.
15. Balsam A & LE Leppo. Effect of physical training on the metabolism of thyroid hormones in man. *J Appl Physiol.* 38: 212–215, 1975.
16. Terjung RL & WW Winder. Exercise and thyroid function. *Med Sci Sports.* 7(1): 20–26, 1974.
17. DeNayer P, M Ostyn & M DeVisscher. Effect de l'entraînement sur le taux de la thyroxine libre chez l'athlète. *Ann D'Endocr.* 31: 721–723, 1970.
18. Ben-Jonathan N, ER Hugo, TG Brandebourg & CR LaPensee. Focus on prolactin as a metabolic hormone. *Trends Endocrinol.* 17(3): 110–116, 2006.
19. Viru A & M Viru. *Biochemical Monitoring of Sport Training*. Human Kinetics Publishing, Champaign, IL, 2001.
20. Daly W, CA Seegers, DA Rubin, JD Dobridge & AC Hackney. Relationship between stress hormones and testosterone with

- prolonged endurance exercise. *Eur J Appl Physiol.* 93: 375–380, 2005.
21. Radomski MW, M Cross & A Buguet. Exercise-induced hyperthermia and hormonal responses to exercise. *Can J Physiol Pharmacol.* 76: 547–552, 1998.
 22. Hackney AC. Characterization of the prolactin response to prolonged endurance exercise. *Acta Kinesiologiae (University of Tartu).* 13: 31–38, 2008.
 23. Ansley L, G Marvin, A Sharma, MJ Kendall, DA Jones & MW Bridge. The effect of head cooling on endurance and neuroendocrine responses to exercise in warm conditions. *Physiol Res.* 57(6): 863–872, 2008.
 24. Hackney AC, RJ Ness & A Schreiber. Effects of endurance exercise on nocturnal hormone concentrations in males. *Chronobiol Int.* 6(4): 341–346, 1989.
 25. Hackney AC, MC Premo & RG McMurray. Influence of aerobic versus anaerobic exercise on the relationship between reproductive hormones in men. *J Sports Sci.* 13(4): 305–311, 1995.
 26. Hackney AC, RL Sharp, WS Runyan & RJ Ness. Relationship of resting prolactin and testosterone changes in males during intensive training. *British J Sports Med.* 23(3): 194, 1989.
 27. Wheeler GD, SR Wall, AN Belcastro & DC Cumming. Reduced serum testosterone and prolactin levels in male distance runners. *JAMA.* 252(4): 514–516, 1984.
 28. Hackney AC, RL Sharp, W Runyan, Y Kim & RJ Ness. Effects of intensive training on the prolactin response to submaximal exercise in males. *J Iowa Acad Sci.* 96(2): 52–53, 1989.
 29. Boyden TW, RW Pamentor, D Grosso, P Stanforth, T Rotkis & JH Wilmore. Prolactin responses, menstrual cycles, and body composition of women runners. *J Clin Endocrinol Metab.* 54(4): 711–714, 1982.
 30. Hackney AC, WE Sinning & BC Bruot. Hypothalamic-pituitary-testicular axis function in endurance trained males. *Int J Sports Med.* 11: 298–303, 1990.
 31. Hackney AC & JD Dobridge. Thyroid hormones and the interrelationship of cortisol and prolactin: influence of prolonged, exhaustive exercise. *Pol J Endocrinol.* 60(4): 252–257, 2009.
 32. Ortega E. Neuroendocrine mediators in the modulation of phagocytosis by exercise: physiological implications. *Exercise Immunol Rev.* 9: 70–93, 2003.
 33. Joyner M & EF Coyle. Endurance exercise performance: the physiology of champions. *J Physiol.* 586: 35–44, 2008.
-
1. Hackney AC, Sinning WE, Bruot BC. Hypothalamic-pituitary-testicular axis function endurance-trained males. *Int J Sports Med.* 1990; 11: 298–303.
 2. Duclos M, Corcuff JB, Rashedi M, Fougere V, Manier G. Does functional alteration of the gonadotropic axis occur in endurance trained athletes during and after exercise? A preliminary study. *Eur J Appl Physiol.* 1996; 73: 427–433.
 3. De Souza MJ, Arce JC, Pescatello LS, Scherzer HS, Luciano AA. Gonadal hormones and semen quality in male runners. A volume threshold effect of endurance training. *Int J Sports Med.* 1994; 15: 383–391.
 4. Wheeler GD, Wall SR, Belcastro AN, Cumming DC. Reduced serum testosterone and prolactin levels in male distance runners. *JAMA.* 1984; 27: 514–516.
 5. Berchtold P, Berger M, Cuppers HJ, Herrmann J, Nieschlag E, Rudorff K, Zimmermann H, Kruskemper HL. Non-gluco-regulatory hormones (T4, T3, rT3, TSH, testosterone) during physical exercise in juvenile type diabetics. *Horm Metab Res.* 1978; 10: 269–273.
 6. Fournier PE, Stalder J, Mermillod B, Chantraine A. Effects of a 110 kilometers ultra-marathon race on plasma hormone levels. *Int J Sports Med.* 1997; 18: 252–256.
 7. Schuermeyer T, Jung K, Nieschlag E. The effect of an 1100 km run on testicular, adrenal and thyroid hormones. *Int J Androl.* 1984; 7: 276–282.
 8. Chicharro JL, Lopez-Mojares LM, Lucia A, Perez M, Alvarez J, Labanda P, Calvo F, Vaquero AF. Overtraining parameters in special military units. *Aviat Space Environ Med* 1998; 69: 562–568.
 9. Marinelli M, Roi GS, Giacometti M, Bonini P, Banfi G. Cortisol, testosterone, and free testosterone in athletes performing a marathon at 4,000 m altitude. *Horm Res.* 1994; 41: 225–229.
 10. Vervoorn C, Quist AM, Vermulst LJ, Erich WB, de Vries WR, Thijssen JH. The behaviour of the plasma free testosterone/cortisol ratio during a season of elite rowing training. *Int J Sports Med.* 1991; 12: 257–263.
 11. Singh A, Petrides JS, Gold PW, Chrousos GP, Deuster PA. Differential hypothalamic-pituitary-adrenal axis reactivity to psychological and physical stress. *J Clin Endocrinol Metab.* 1999; 84: 1944–1948.
 12. Opstad PK. The hypothalamo-pituitary regulation of androgen secretion in young men after prolonged physical stress combined with energy and sleep deprivation. *Acta Endocrinol (Copenh).* 1992; 127: 231–236.
 13. Bernton E, Hoover D, Galloway R, Popp K. Adaptation to chronic stress in military trainees. Adrenal androgens, testosterone, glucocorticoids, IGF-1, and immune function. *Ann N Y Acad Sci.* 1995; 29: 217–231.
 14. Slowinska-Lisowska M, Jozkow P, Medras M. Associations between physical activity and the androgenic/estrogenic status of men. *Physiol Res.* 2010 Apr 20. [Epub ahead of print].
 15. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. *Mech Ageing Dev.* 1999; 107: 123–136.

16. Ramos E, Frontera WR, Llopart A, Feliciano D. Muscle strength and hormonal levels in adolescents: gender related differences. *Int J Sports Med.* 1998; 19: 526–531.
 17. Kraemer WJ, Staron RS, Hagerman FC, Hikida RS, Fry AC, Gordon SE, Nindl BC, Gothshalk LA, Volek JS, Marx JO, Newton RU, Hakkinen K. The effects of short-term resistance training on endocrine function in men and women. *Eur J Appl Physiol.* 1998; 78: 69–76.
 18. Hakkinen K, Pakarinen A, Newton RU, Kraemer WJ. Acute hormone responses to heavy resistance lower and upper extremity exercise in young versus old men. *Eur J Appl Physiol.* 1998; 77: 312–319.
 19. Kraemer RR, Kilgore JL, Kraemer GR, Castracane VD. Growth hormone, IGF-I, and testosterone responses to resistive exercise. *Med Sci Sports Exerc.* 1992; 24: 1346–1352.
 20. Jurimae T, Karelson K, Smirnova T, Viru A. The effect of a single-circuit weight-training session on the blood biochemistry of untrained university students. *Eur J Appl Physiol.* 1990; 61: 344–348.
 21. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. *N Engl J Med.* 1996; 335: 1–7.
 22. Craig BW, Brown R, Everhart J. Effects of progressive resistance training on growth hormone and testosterone levels in young and elderly subjects. *Mech Ageing Dev.* 1989; 49: 159–169.
 23. Fry AC, Kraemer WJ, Ramsey LT. Pituitary-adrenal-gonadal responses to high-intensity resistance exercise overtraining. *J Appl Physiol.* 1998; 85: 2352–2359.
 24. Derbré F, Vincent S, Maitel B, Jacob C, Delamarche P, Delamarche A, Zouhal H. Androgen responses to sprint exercise in young men. *Int J Sports Med.* 2010; 31: 291–297.
 25. Budde H, Pietrassyk-Kendziorra S, Bohm S, Voelcker-Rehage C. Hormonal responses to physical and cognitive stress in a school setting. *Neurosci Lett.* 2010; 474: 131–134.
 26. Schulz P, Walker JP, Peyrin L, Soulier V, Curtin F, Steimer T. Lower sex hormones in men during anticipatory stress. *Neuroreport.* 1996; 25: 3101–3104.
 27. Francis KT. The relationship between high and low trait psychological stress, serum testosterone, and serum cortisol. *Experientia.* 1981; 37(12): 1296–1297.
 28. Nilsson PM, Moller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. *J Intern Med.* 1995; 237: 479–486.
 29. MacLean CR, Walton KG, Wenneberg SR, Levitsky DK, Mandarino JP, Waziri R, Hillis SL, Schneider RH. Effects of the transcendental meditation program on adaptive mechanisms: changes in hormone levels and responses to stress after 4 months of practice. *Psychoneuroendocrinology.* 1997; 22: 277–295.
 30. Grossi G, Theorell T, Jurisoo M, Setterlind S. Psychophysiological correlates of organizational change and threat of unemployment among police inspectors. *Integr Physiol Behav Sci.* 1999; 34: 30–42.
-
1. Braun B, Brooks GA. Critical importance of controlling energy status to understand the effects of “exercise” on metabolism. *Exerc Sport Sci Rev* 2008; 36:2–4.
 2. Selye H. The effect of adaptation to various damaging agents on the female sex organs in the rat. *Endocrinology* 1939; 25:615–624.
 3. Selye H. A syndrome produced by diverse nocuous agents. *Nature* 1936; 138:32.
 4. Selye H. Adaptation energy. *Nature* 1938; 141:926.
 5. Wertheimer H. Introduction – a perspective. In: Renold A, Cahill G Jr, eds. *Handbook of Physiology Section 5: Adipose Tissue.* Washington: American Physiological Society 1965; 5–11.
 6. Loucks A. Is stress measured in joules? *Military Psychol* 2009; 21:S101–S107.
 7. Loucks AB, Mortola JF, Girton L, Yen SSC. Alterations in the hypothalamic-pituitary-ovarian and the hypothalamic-pituitary-adrenal axes in athletic women. *J Clin Endocrinol Metab* 1989; 68:402–411.
 8. Laughlin GA, Yen SSC. Nutritional and endocrine-metabolic aberrations in amenorrheic athletes. *J Clin Endocrinol Metab* 1996; 81:4301–4309.
 9. Loucks AB, Verdun M, Heath EM. Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. *J Appl Physiol* 1998; 84:37–46.
 10. Williams NI, Caston-Balderrama AL, Helmreich DL, Parfitt DB, Nosbisch C, Cameron JL. Longitudinal changes in reproductive hormones and menstrual cyclicity in cynomolgus monkeys during strenuous exercise training: abrupt transition to exercise-induced amenorrhea. *Endocrinology* 2001; 142:2381–2389.
 11. Williams NI, Helmreich DL, Parfitt DB, Caston-Balderrama AL, Cameron JL. Evidence for a causal role of low energy availability in the induction of menstrual cycle disturbances during strenuous exercise training. *J Clin Endocrinol Metab* 2001; 86:5184–5193.
 12. Loucks AB. The response of luteinizing hormone pulsatility to five days of low energy availability disappears by 14 years of gynecological age. *J Clin Endocrinol Metab* 2006; 91:3158–3164.
 13. Baker ER, Mathur RS, Kirk RF, Williamson HO. Female runners and secondary amenorrhea: correlation with age, parity, mileage, and plasma hormonal and sex-hormone-binding globulin concentrations. *Fertil Steril* 1981; 36:183–187.
 14. Vollman RF. The menstrual cycle. In: Friedman EA, ed. *Major Problems in Obstetrics and Gynecology, Vol 7.* Philadelphia: W.B. Saunders 1977:193.

15. Ellison PT. Advances in human reproductive ecology. *Annu Rev Anthropol* 1994; 23:255–275.
16. Loucks AB, Thuma JR. Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. *J Clin Endocrinol Metab* 2003; 88:297–311.
17. Loucks AB. Low energy availability in the marathon and other endurance sports. *Sports Med* 2007; 37:348–52.
18. Kopp-Woodroffe SA, Manore MM, Dueck CA, Skinner JS, Matt KS. Energy and nutrient status of amenorrheic athletes participating in a diet and exercise training intervention program. *Int J Sport Nutr* 1999; 9:70–88.
19. Ihle R, Loucks AB. Dose-response relationships between energy availability and bone turnover in young exercising women. *J Bone Miner Res* 2004; 19:1231–1240.
20. Nattiv A, Loucks AB, Manore MM, Sundgot-Borgen J, Warren MP. American College of Sports Medicine Position Stand: The female athlete triad. *Med Sci Sports Exerc* 2007; 39:1867–1882.

1. Hossain P, Kawar B et al. Obesity and diabetes in the developing world – a growing challenge. *N Engl J Med* 2007; 356: 213–215.
2. Maffeis C. Physical activity: an effective way to control weight in children? *Nutr Metab Cardiovasc Dis* 2007; 17: 394–408.
3. Hood DA, Salem A. Exercise-induced mitochondrial biogenesis in skeletal muscle. *Nutr Metab Cardiovasc Dis* 2007; 17: 332–337.
4. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites on non-insulin- and insulin-mediated glucose uptake in humans. *Am J Physiol* 1988; 255: E769–E774.
5. Laaksonen DE et al. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. *Diabetes Care* 2002; 25: 1612–1618.
6. Brage S et al. European Youth Heart Study (EYHS). Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children: the European Youth Heart Study (EYHS). *Diabetes Care* 2004; 27: 2141–2148.
7. Wisloff U, Najjar SM et al. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. *Science* 2005; 307: 418–420.
8. Kelley DE et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. *Diabetes* 2002; 51: 2944–2950.
9. De Feo P, Stocchi V. Physical activity for the treatment and prevention of metabolic syndrome. *Nutr Metab Cardiovasc Dis* 2007; 17: 327–331.
10. Guescini M et al. Fine needle aspiration coupled with real-time PCR: a painless methodology to study adaptive functional changes in skeletal muscle. *Nutr Metab Cardiovasc Dis* 2007; 17: 383–393.
11. Cooper JM, Mann VM, Shapira AH. Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. *J Neurol Sci* 1992; 98: 113–191.
12. Coggan AR, Spina RJ, Kings DS, Rogers MA, Brown M, Nemeth PM, Holloszy JO. Histochemical and enzymatic comparison of the gastrocnemius muscle of young and elderly men and women. *J Gerontol* 1992; 47: B71–B76.
13. Short KR, Bigelow ML, Kahl J et al. Decline in skeletal muscle mitochondrial function with aging in humans. *Proc Natl Acad Sci USA* 2005; 102: 5618–5623.
14. Simoneau JA, Colberg SR, Thaete FL, Kelley DE. Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. *FASEB J* 1995; 9: 273–278.
15. Mootha V, Lindgren CM, Eriksson KF et al. PGC-1 α responsive genes involved in oxidative phosphorylation are co-ordinately downregulated in human diabetes. *Nat Genet* 2003; 34: 267–273.
16. Patti M, Butte A, Crunkhorn S et al. Coordinated reduction on genes of oxidative metabolism in humans with insulin resistance and diabetes: potential roles of PGC1 and NRF-1. *Proc Natl Acad Sci USA* 2003; 100: 8466–8471.
17. Rönn T, Poulsen P, Hansson O et al. Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle. *Diabetologia* 2008; 51: 1159–1168.
18. De Feo P, Di Loreto C, Ranchelli A et al. Physical inactivity is the main cause of the metabolic syndrome. In: Stocchi V, de Feo P, Hood DA (eds) *Role of physical exercise in preventing disease and improving the quality of life*. Milan: Springer 2007; 23–33.
19. Dohm GL, Huston RL, Askew EW, Fleshood HL. Effects of exercise, training, and diet on muscle citric acid cycle enzyme activity. *Can J Biochem* 1973; 51: 849–854.
20. Holloszy JO, Oscai LB, Dohn IJ, Molé PA. Mitochondrial citric acid cycle and related enzymes: adaptive response to exercise. *Biochem Biophys Res Commun* 1970; 40: 1368–1373.
21. Hoppeler H, Luthi P, Claassen H, Weibel ER, Howald H. The ultrastructure of the normal human skeletal muscle. A morphometric analysis on untrained men, women and well trained orienteers. *Pfuegers Arch* 1973; 344: 217–232.
22. Coggan AR, Spina RJ, Kings DS, Rogers MA, Brown M, Nemeth PM, Holloszy JO. Skeletal muscle adaptations to endurance training in 60- to 70-yr-old men and women. *J Appl Physiol* 1992; 72: 1780–1786.
23. Jubrias SA, Esselman PC, Price LB, Cress ME, Conley KE. Large energetic adaptations of elderly muscle to resistance and endurance training. *J Appl Physiol* 2001; 90: 1663–1670.
24. Menshikova EV, Ritov VB, Fairfull L, Ferrell RE, Kelley DE, Goodpaster BH. Effects of exercise on mitochondrial content and function in aging human skeletal muscle. *J Gerontol A Biol Sci Med Sci* 2006; 61: 534–540.
25. Toledo FGS, Menshikova EV, Ritov VB, Azuma K, Radikova Z, DeLany J, Kelley DE. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. *Diabetes* 2007; 56: 2142–2147.

26. Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. *JAMA* 2001; 286: 1218–1227.
27. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2006; (3): CD002968.
28. Dunstan DW, Daly RM, Owen N, Jolley D, De Courten M, Shaw J, Zimmet P. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. *Diabetes Care* 2002; 25: 1729–1736.
29. Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, Foldvari M, Roubenoff R, Tucker KL, Nelson ME. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. *Diabetes Care* 2002; 25: 2335–2341.
30. Balducci S, Leonetti F, Di Mario U, Fallucca F. Is a long-term aerobic plus resistance training program feasible for and effective on metabolic profiles in type 2 diabetic patients? *Diabetes Care* 2004; 27: 841–842.
31. Sigal RJ, Kenny GP, Boulé NG, Wells GA, Prud'homme D, Fortier M, Reid RD, Tulloch H, Coyle D, Phillips P, Jennings A, Jaffey J. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. *Ann Intern Med*. 2007; 147: 357–369.
32. Kraus WE, Levine BD. Exercise training for diabetes: the “strength” of the evidence. *Ann Intern Med* 2007; 147: 423–424.
33. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical activity/ exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. *Diabetes Care* 2006; 29: 1433–1438.
34. Di Loreto C, Fanelli C, Lucidi P, et al. Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. *Diabetes Care* 2005; 28: 1295–1302.
35. Di Loreto C, Fanelli C, Lucidi P et al. Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects. *Diabetes Care* 2003; 26: 404–408.
36. De Feo P, Di Loreto C, Lucidi P, Murdolo G, Parlanti N, De Cicco A, Piccioni F, Santeusano F. Metabolic response to exercise. *J Endocrinol Invest* 2003; 26: 851–854.
37. Bajpeyi S, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Hickner RC, Kraus WE, Houmard JA. Effect of exercise intensity and volume on the persistence of insulin sensitivity during training cessation. *J Appl Physiol* 2009; 106: 1079–1085.
38. Kirk A, De Feo P. Strategies to enhance compliance to physical activity for patients with insulin resistance. *Appl Physiol Nutr Metab* 2007; 32: 549–556.

1. Duchateau J, Semmler JG, Enoka RM. Training adaptations in the behavior of human motor units. *J Appl Physiol* 2006; 101:1766–1775.
2. Heckman CJ, Lee RH, Bronstone RM. Hyperexcitable dendrites in motoneurons and their neuromodulatory control during motor behaviour. *Trends Neurosci* 2003; 26:688–695.
3. Brownstone RM. Beginning at the end: repetitive firing properties in the final common pathway. *Prog Neurobiol* 2006; 78:156–172.
4. Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. *N Engl J Med* 1995; 332:1351–1362.
5. Valentino RJ, Foote SL, Page ME. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. *Ann N Y Acad Sci* 1993; 697: 173–188.
6. Van Bockstaele EJ, Colago EEO, Valentino RJ. Corticotropin-releasing factor-containing axon terminals synapse onto catecholamine dendrites and may presynaptically modulate other afferents in the rostral pole of the nucleus locus coeruleus in the rat brain. *J Comp Neurol* 1996; 364:523–534.
7. Curtis AL, Florin-Lechner SM, Pavcovich LA, et al. Activation of the locus coeruleus noradrenergic system by intracoeular microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. *J Pharmacol Exp Ther* 1997; 281:163–172.
8. Sakanaka M, Shibasaki T, Lederis K. Corticotropin releasing factor-like immunoreactivity in the rat brain as revealed by a modified cobalt-glucose oxidase-diaminobenzidine method. *J Comp Neurol* 1987; 260:256–298.
9. Price ML, Curtis AL, Kirby LG, et al. Effects of corticotropin-releasing factor on brain serotonergic activity. *Neuropsychopharmacology* 1998; 18:492–502.
10. Waselus M, Valentino RJ, Van Bockstaele EJ. Ultrastructural evidence for a role of gammaaminobutyric acid in mediating the effects of corticotropin-releasing factor on the rat dorsal raphe serotonin system. *J Comp Neurol* 2005; 482:155–165.
11. Owczarek J, Jasi ska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. *Pharmacol Rep* 2005; 57:23–34.
12. Wu FC. Endocrine aspects of anabolic steroids. *Clin Chem* 1997; 43:1289–1292.
13. Goldspink G. Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. *J Anat* 1999; 194: 323–334.
14. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50 years later. *J Clin Endocrinol Metab* 2007; 92:4529–4535.
15. Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. *Endocrinology* 2001;142:1489–1496.
16. O'Connor JC, McCusker RH, Strle K, et al. Regulation of IGF-I function by proinflammatory cytokines: at the interface of

- immunology and endocrinology. *Cell Immunol* 2008; 252:91–110.
17. Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal muscle. *Endocrinology* 1995; 136:3669–3672.
 18. Quinn LS, Haugk KL, Damon SE. Interleukin-15 stimulates C2 skeletal myoblast differentiation. *Biochem Biophys Res Commun* 1997; 239:6–10.
 19. Navegantes LC, Migliorini RH, do Carmo Kettelhut I. Adrenergic control of protein metabolism in skeletal muscle. *Curr Opin Clin Nutr Metab Care* 2002; 5:281–286.
 20. Simonides WS, van Hardeveld C. Thyroid hormone as a determinant of metabolic and contractile phenotype of skeletal muscle. *Thyroid* 2008; 18:205–216.
 21. Chargé SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. *Physiol Rev* 2004; 84:209–238.
 22. Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. *J Physiol* 2003; 549:409–418.
 23. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature* 1997; 387:83–90.
 24. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. *N Engl J Med* 2004; 350:2682–2688.
 25. Filigheddu N, Gnocchi VF, Coscia M, et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. *Mol Biol Cell* 2007; 18:986–994.
 26. Lebrasseur NK, Coté GM, Miller TA, et al. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. *Am J Physiol Cell Physiol* 2003; 284:C1149–C1155.
 27. van der Hoeven JH. Decline of muscle fiber conduction velocity during short-term high-dose methylprednisolone therapy. *Muscle Nerve* 1996; 19:100–102.
-
1. Malina RM, Bouchard C, Bar-Or O. The young athlete. In: Malina RM, Bouchard C, Bar-Or O, editors. *Growth, Maturation and Physical Activity*, 2nd edition. Human Kinetics Press, Champaign, IL, 2004, pp 623–49.
 2. Tanner JM. *Growth at Adolescence*. Springfield, Charles C. Thomas, 1962.
 3. Zachmann M, Prader A, Kind HP, et al. Testicular volume during adolescence: cross-sectional and longitudinal studies. *Helv Paediatr Acta*. 1974; 29:61–72.
 4. Tanner JM, Whitehouse RH, Marubini E, Resele LF. The adolescent growth spurt of boys and girls of the Harpenden growth study. *Ann Hum Biol*. 1976; 3:109–26.
 5. Largo RH. Analysis of the adolescent growth spurt using smoothing spline function. *Ann Hum Biol*. 1978; 5:421–34.
 6. Greulich WS, Pyle SI. *Radiograph Atlas of Skeletal Development of the Hand and Wrist*. Stanford: Stanford University Press, 1959.
 7. Veldhuis JD, Roemmich JN, Richmind EJ, et al. Endocrine control of body composition in infancy, childhood, and puberty. *Endocr Rev*. 2005; 26:114–46.
 8. Albertsson-Wikland K, Rosberg S, Lannering B, et al. Twenty-four-hour profiles of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol levels: a semi-longitudinal study throughout puberty in healthy boys. *J Clin Endocrinol Metab*. 1997; 82:541–9.
 9. Knobil E. The neuroendocrine control of the menstrual cycle. *Recent Prog Horm Res*. 1980; 36:53–88.
 10. Knorr D. Plasma testosterone in male puberty. 1. Physiology of plasma testosterone. *Acta Endocrinol (Copenh)*. 1974; 75:181–94.
 11. Melmed S, Klineberg D. Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. *Williams Textbook of Endocrinology*, 11th edition. Sanders (Elsevier), New York, 2008, pp 155–261.
 12. Roemmich, JN, Huerta MG, Sundaresan SM, Rogol AD. Alterations in body composition and fat distribution in growth hormone deficient prepubertal children during growth hormone therapy. *Metabolism*. 2001; 50:537–47.
 13. Holland-Hall C. Performance-enhancing substances: is your adolescent patient using? *Pediatr Clin N Am*. 2007; 54:651–62.
 14. American Academy of Pediatrics Committee on Sports Medicine and Fitness. Use of performance-enhancing substances. *Pediatrics*. 2005; 115:1103–6.
 15. Carpenter PC. Performance-enhancing drugs in sport. *Endocrinol Metab Clin N Am*. 2007; 36:481–95.
 16. Castillo EM, Comstock RD. Prevalence of use of performance-enhancing substances among United States adolescents. *Pediatr Clin N Am*. 2007; 54:66375.
 17. Smurawa TM, Congeni JA. Testosterone precursors: use and abuse in pediatric athletes. *Pediatr Clin N Am*. 2007; 54:787–96.
 18. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. *Int J Androl*. 2003; 26:76–83.
 19. World Anti-Doping Agency. <http://www.wada-ama.org/>, accessed Jan 03, 2009.
 20. Liu H, Bravata DM, Okin I, et al. Systematic review: the effects of growth hormone on athletic performance. *Ann Int Med*. 2008; 144:747–58.
 21. Richmond EJ, Rogol AD. Recombinant human insulin-like growth factor-I therapy for children with growth disorders. *Adv Ther*.

- 2008; 25:1276–87.
22. Thomas A, Thevis M, Delahaut P, et al. Mass spectrometric identification of degradation products of insulin and its long-acting analogues in human urine for doping control purposes. *Anal Chem.* 2007; 79:2518–24.
 23. Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. *Brit J Pharmacol.* 2008; 154:529–41.
 24. Macdougall IC. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. *Curr Opin Investig Drugs.* 2008; 9:1034–47.
 25. Topf JM. CERA: third generation erythropoiesis-stimulating agent. *Expert Opin Pharmacother.* 2008; 9:839–49.
 26. Bunn HF. New agents that stimulate erythropoiesis. *Blood.* 2007; 109:868–73.
 27. Barton-Davis ER, Shoturma DI, Musaro A, et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. *Proc Natl Acad Sci USA.* 1998; 95:15603–7.
 28. Wells DJ. Gene doping: the hype and the reality. *Brit J Pharmacol.* 2008; 154:623–31.
 29. Goldspink G, Yang SY, Hameed M, et al. The role of MGF and other IGF-I splice variants in muscle maintenance and hypertrophy. In: Kraemer WJ and Rogol AD, editors. *The Endocrine System in Sports and Exercise. Vol XI, The Encyclopaedia of Sports Medicine, an IOC Medical Commission Publication.* Blackwell Publishing, Malden, MA, 2005, pp 180–93.
 30. Joulia-Ekaza D, Cabello G. The myostatin gene: physiology and pharmacological relevance. *Curr Opin Pharmacol.* 2007; 7:310–5.
 31. Kraemer DK, Ahlsen M, Norrbom J, et al. Human skeletal muscle fibre type variations correlate with PPAR alpha, PPAR delta and PGC-1 alpha mRNA. *Acta Physiol (Oxf).* 2007; 188:207–16.
 32. Wang YX, Zhang CL, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARdelta. *PLoS Biol.* 2004; 2:e294.
-
1. Wilson JD. Androgen abuse by athletes. *Endocr Rev.* 1988; 9:181–199.
 2. Bhasin S, Calof O, Storer TW, et al. Drug insights: anabolic applications of testosterone and selective androgen receptor modulators in aging and chronic illness. *Nat Clin Pract Endocrinol Metab.* 2006; 2:133–140.
 3. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2006; 91:1995–2010.
 4. Yesalis CE, III, Bahrke MS, Kopstein AN, Baruskiewicz CK. Incidence onabolic steroid use: a discussion of methodological issues. In: Yesalis CE, III ed. 2000. *Anabolic steroids in sports and exercise, Second ed.* Champaign, IL: Human Kinetics; 73–115.
 5. Yesalis CE, Barsukiewicz CK, Kopstein AN, Bahrke MS. Trends in anabolic-androgenic steroid use among adolescents. *Arch Pediatr Adolesc Med.* 1997; 151:1197–1206.
 6. Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. *JAMA.* 1993; 270:1217–1221.
 7. Hoffman JR, Kraemer WJ, Bhasin S, Storer T, Ratamess NA, Haff GG, Willoughby DS, Rogol AD. Position stand on androgen and human growth hormone use. *J Strength Cond Res/ National Strength & Conditioning Association.* 2009; 23:S1–S59.
 8. Medicine ACoS. Position stand: the use of anabolic-androgenic steroids in sports. *Med Sci Sports Exerc.* 1987; 19:534–539.
 9. Catlin DH, Fitch KD, Ljungqvist A. Medicine and science in the fight against doping in sport. *J Intern Med.* 2008; 264:99–114.
 10. Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. *Acta Endocrinol Suppl (Copenh).* 1985; 271:11–18.
 11. McDuff DR, Baron D. Substance use in athletics: a sports psychiatry perspective. *Clin Sports Med.* 2005; 24:885–897, ix–x.
 12. Noakes TD. Tainted glory – doping and athletic performance. *N Engl J Med.* 2004; 351:847–849.
 13. Prendergast HM, Bannen T, Erickson TB, Honore KR. The toxic torch of the modern Olympic Games. *Vet Hum Toxicol.* 2003; 45:97–102.
 14. Wadler GI. Drug use update. *Med Clin North Am.* 1994; 78:439–455.
 15. Shackleton C. Steroid analysis and doping control 1960–1980: scientific developments and personal anecdotes. *Steroids.* 2009; 74:288–295.
 16. Wade N. Anabolic steroids: doctors denounce them, but athletes aren't listening. *Science.* 1972; 176:1399–1403.
 17. Yesalis CE, Courson SP, Wright JE. History of anabolic steroid use in sport and exercise. In: Yesalis CE ed. *Anabolic steroids in sports and exercise.* 2000. Champaign, IL: Human Kinetics; 51–72.
 18. Yamaguchi R, Johnston LD, O'Malley PM. Relationship between student illicit drug use and school drug-testing policies. *J Sch Health.* 2003; 73:159–164.
 19. Clifford PR, Edmundson E, Koch WR, Dodd BG. Discerning the epidemiology of drug use among a sample of college students. *J Drug Educ.* 1989; 19:209–223.
 20. McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. *Drug Alcohol Depend.* 2007; 90:243–251.
 21. Evans NA. Gym and tonic: a profile of 100 male steroid users. *Br J Sports Med.* 1997; 31:54–58.
 22. Evans NA. Local complications of self administered anabolic steroid injections. *Br J Sports Med.* 1997; 31:349–350.

23. Pope HG, Jr., Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. *Arch Gen Psychiatry*. 1994; 51:375–382.
24. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. *Med Sci Sports Exerc*. 2006; 38:644–651.
25. Evans NA. Current concepts in anabolic-androgenic steroids. *Am J Sports Med*. 2004; 32:534–542.
26. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. *J Clin Endocrinol Metab*. 1997; 82:407–413.
27. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men – a clinical research center study. *J Clin Endocrinol Metab*. 1996; 81:3469–3475.
28. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol Metab*. 2004; 89:2085–2098.
29. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. *J Clin Endocrinol Metab*. 2000; 85:2670–2677.
30. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. *J Clin Endocrinol Metab*. 2003; 88:2673–2681.
31. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. *J Clin Endocrinol Metab*. 1998; 83:1886–1892.
32. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. *N Engl J Med*. 1996; 335:1–7.
33. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. *Sports Med*. 2004; 34:513–554.
34. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. *Am J Physiol Endocrinol Metab*. 2001; 281:E1172–E1181.
35. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, Bhasin S. Development of models to predict anabolic response to testosterone administration in healthy young men. *Am J Physiol Endocrinol Metab*. 2003; 284:E1009–E1017.
36. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays RD, Beall G. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. *JAMA*. 2000; 283:763–770.
37. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parلمان K, Anderson E, Basgoz N, Klibanski A. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 1998; 129:18–26.
38. Grinspoon S, Corcoran C, Stanley T, Katznelson L, Klibanski A. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting. *J Clin Endocrinol Metab*. 1998; 83:4251–4256.
39. Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, Fournier M, Storer TW. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2004; 170:870–878.
40. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. *J Clin Endocrinol Metab*. 1999; 84:2647–2653.
41. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. *J Clin Endocrinol Metab*. 2004; 90(3):1502–1510.
42. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. *J Gerontol A Biol Sci Med Sci*. 2001; 56:M266–M272.
43. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. *J Clin Endocrinol Metab*. 2003; 88:1478–1485.
44. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. *J Clin Endocrinol Metab*. 2008; 93:914–919.
45. Blanco CE, Popper P, Micevych P. Anabolic-androgenic steroid induced alterations in choline acetyltransferase messenger RNA levels of spinal cord motoneurons in the male rat. *Neuroscience*. 1997; 78:873–882.
46. Blanco CE, Zhan WZ, Fang YH, Sieck GC. Exogenous testosterone treatment decreases diaphragm neuromuscular transmission failure in male rats. *J Appl Physiol*. 2001; 90:850–856.
47. Leslie M, Forger NG, Breedlove SM. Sexual dimorphism and androgen effects on spinal motoneurons innervating the rat flexor digitorum brevis. *Brain Res*. 1991; 561:269–273.
48. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, Storer TW, Casaburi R, Shen R, Bhasin S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. *Am J Physiol Endocrinol Metab*. 2002; 283:E154–E164.

49. Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. *Br J Pharmacol.* 2008; 154:522–528.
50. Kadi F, Bonnerud P, Eriksson A, Thornell LE. The expression of androgen receptors in human neck and limb muscles: effects of training and self-administration of androgenic-anabolic steroids. *Histochem Cell Biol.* 2000; 113:25–29.
51. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. *Am J Physiol Endocrinol Metab.* 2003; 285:E197–E205.
52. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. *J Clin Endocrinol Metab.* 2004; 89:5245–5255.
53. MacLean HE, Chiu WS, Ma C, McManus JF, Davey RA, Cameron R, Notini AJ, Zajac JD. A floxed allele of the androgen receptor gene causes hyperandrogenization in male mice. *Physiol Genomics.* 2008; 33:133–137.
54. Ophoff J, Van Proeyen K, Callewaert F, De Gendt K, De Bock K, Vanden Bosch A, Verhoeven G, Hespel P, Vanderschueren D. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. *Endocrinology.* 2009; 150:3558–3566.
55. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. *Endocrinology.* 2006; 147:141–154.
56. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. *Endocrinology.* 2003; 144:5081–5088.
57. Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB, Jasuja R. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/beta-catenin and follistatin/transforming growth factor-beta signaling pathways. *Endocrinology.* 2009; 150:1259–1268.
58. Jasuja R, Ulloor J, Yengo CM, Choong K, Istomin AY, Livesay DR, Jacobs DJ, Swerdloff RS, Miksovska J, Larsen RW, Bhasin S. Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain. *Mol Endocrinol.* 2009; 23:1231–1241.
59. Kochakian CD, Cohn L, et al. Effect of testosterone propionate on nitrogen and chloride excretion and body weight of castrated rats during recovery from fasting. *Am J Physiol.* 1948; 155:272–277.
60. Kochakian CD, Costa G. The effect of testosterone propionate on the protein and carbohydrate metabolism in the depancreatized-castrated dog. *Endocrinology.* 1959; 65:298–309.
61. Urban RJ, Bodenbun YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. *Am J Physiol.* 1995; 269:E820–E826.
62. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ. Differential anabolic effects of testosterone and amino acid feeding in older men. *J Clin Endocrinol Metab.* 2003; 88:358–362.
63. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. *Am J Physiol Endocrinol Metab* 2002; 282:E601–E607.
64. Choong K, Lakshman KM, Bhasin S. The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports. *Asian J Androl.* 2008; 10:351–363.
65. Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weighttrained women athletes. *JAMA.* 1985; 253:2871–2873.
66. Strauss RH, Yesalis CE. Anabolic steroids in the athlete. *Annu Rev Med.* 1991; 42:449–457.
67. Bahrke MS, Wright JE, Strauss RH, Catlin DH. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. *Am J Sports Med.* 1992; 20:717–724.
68. Bahrke MS, Wright JE, O'Connor JS, Strauss RH, Catlin DH. Selected psychological characteristics of anabolic-androgenic steroid users. *N Engl J Med.* 1990; 323:834–835.
69. Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. *Int J Sports Med.* 2000; 21:225–227.
70. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review *Arch Intern Med.* 1991; 151:1925–1933.
71. Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. *Psychoneuroendocrinology.* 2003; 28:317–331.
72. Payne AH, Quinn PG, Rani CS. Regulation of microsome cytochrome P-450 enzymes and testosterone production in Leydig cells. *Recent Prog Horm Res.* 1985; 41:153–197.
73. Ansell JE, Tiarks C, Fairchild VK. Coagulation abnormalities associated with the use of anabolic steroids. *Am Heart J.* 1993; 125:367–371.
74. Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. *Liver.* 1992; 12:73–79.
75. Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: is it overstated? *Clin J Sport Med.* 1999; 9:34–39.
76. Pertusi R, Dickerman RD, McConathy WJ. Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids:

- hepatitis or rhabdomyolysis? *J Am Osteopath Assoc.* 2001; 101:391–394.
77. Green GA, Uryasz FD, Petr TA, Bray CD. NCAA study of substance use and abuse habits of college student-athletes. *Clin J Sport Med.* 2001; 11:51–56.
78. Petersson A, Garle M, Holmgren P, Druid H, Krantz P, Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. *Drug Alcohol Depend.* 2006; 81:241–249.
79. Petersson A, Garle M, Granath F, Thiblin I. Morbidity and mortality in patients testing positively for the presence of anabolic androgenic steroids in connection with receiving medical care. A controlled retrospective cohort study. *Drug Alcohol Depend.* 2006; 81:215–220.
80. Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. *J Forensic Sci.* 2000; 45:16–23.
81. Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. *Ann Clin Psychiatry.* 1999; 11:223–231.
82. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. *Med Sci Sports Exerc.* 1995; 27:1252–1262.
83. Bonetti A, Tirelli F, Catapano A, Dazzi D, Dei Cas A, Solito F, Ceda G, Reverberi C, Monica C, Pipitone S, Elia G, Spattini M, Magnati G. Side effects of anabolic androgenic steroids abuse. *Int J Sports Med.* 2007; 29(8):679–687.
84. Dhar R, Stout CW, Link MS, Homoud MK, Weinstock J, Estes NA, III. Cardiovascular toxicities of performance-enhancing substances in sports. *Mayo Clin Proc.* 2005; 80:1307–1315.
85. Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala TA. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. *Int J Sports Med.* 2003; 24:337–343.
86. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. *Prog Cardiovas Dis.* 1998; 41:1–15.
87. Nieminen MS, Ramo MP, Viitasalo M, Heikkila P, Karjalainen J, Mantysaari M, Heikkila J. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. *Eur Heart J.* 1996; 17:1576–1583.
88. Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. *Toxicol Lett.* 2005; 158:167–175.
89. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. *Clin Endocrinol (Oxf).* 2002; 57:209–214.
90. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. *Int J Impot Res.* 2006; 18:494–498.
91. Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, Mazer NA. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. *J Clin Endocrinol Metab.* 2001; 86:1026–1033.
92. Friedl KE. Reappraisal of the health risks associated with the use of high doses of oral and injectable androgenic steroids. *NIDA Res Monogr.* 1990; 102:142–177.
93. Friedl KE, Hannan CJ, Jr., Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. *Metabolism.* 1990; 39:69–74.
94. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. *Am J Med.* 2001; 111:261–269.
95. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. *Clin Endocrinol (Oxf).* 2005; 63:280–293.
96. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. *J Clin Endocrinol Metab.* 2002; 87:136–143.
97. Jockenhovel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Muller-Wieland D, Krone W. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. *Metabolism.* 1999; 48:590–596.
98. Dickerman RD, McConathy WJ, Schaller F, Zachariah NY. Cardiovascular complications and anabolic steroids. *Eur Heart J.* 1996; 17:1912.
99. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. *Med J Aust.* 1993; 158:346–348.
100. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. *Heart (British Cardiac Society).* 2004; 90:473–475.
101. De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. *Int J Sports Med.* 1991; 12:408–412.
102. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? *Heart (British Cardiac Society).* 2004; 90:496–501.
103. Stolt A, Karila T, Viitasalo M, Mantysaari M, Kujala UM, Karjalainen J. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. *Am J Cardiol.* 1999; 84:364–366, A369.
104. Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death – a case report and review of the literature. *Int J Legal Med.* 1998; 111:261–264.

105. Di Paolo M, Agozzino M, Toni C, Luciani AB, Molendini L, Scaglione M, Inzani F, Pasotti M, Buzzi F, Arbustini E. Sudden anabolic steroid abuse-related death in athletes. *Int J Cardiol.* 2007; 114:114–117.
106. Dickerman RD, Schaller F, Prather I, McConathy WJ. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. *Cardiology.* 1995; 86:172–173.
107. Fineschi V, Baroldi G, Monciotti F, Paglicci Reattelli L, Turillazzi E. Anabolic steroid abuse and cardiac sudden death: a pathologic study. *Arch Pathol Lab Med.* 2001; 125:253–255.
108. Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G, Karch SB. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. *Int J Legal Med.* 2007; 121:48–53.
109. Luke JL, Farb A, Virmani R, Sample RH. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. *J Forensic Sci.* 1990; 35:1441–1447.
110. Pye M, Quinn AC, Cobbe SM. QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias? *Br Heart J.* 1994; 71:511–514.
111. Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, Bhasin S. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men – a clinical research center study. *J Clin Endocrinol Metab.* 1996; 81:3754–3758.
112. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. Neuropsychiatric effects of anabolic steroids in male normal volunteers. *JAMA.* 1993; 269:2760–2764.
113. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. *Biol Psychiatry.* 1999; 45:254–260.
114. Kouri EM, Lukas SE, Pope HG, Jr., Oliva PS. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. *Drug Alcohol Depend.* 1995; 40:73–79.
115. Pope HG, Jr., Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. *Arch Gen Psychiatry.* 2000; 57:133–140; discussion 155–136.
116. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. *J Clin Endocrinol Metab.* 1996; 81:3578–3583.
117. Midgley SJ, Heather N, Davies JB. Levels of aggression among a group of anabolic-androgenic steroid users. *Med Sci Law.* 2001; 41:309–314.
118. Klotz F, Garle M, Granath F, Thiblin I. Criminality among individuals testing positive for the presence of anabolic androgenic steroids. *Arch Gen Psychiatry.* 2006; 63:1274–1279.
119. Pope HG, Jr., Katz DL. Homicide and near-homicide by anabolic steroid users. *J Clin Psychiatry.* 1990; 51:28–31
120. Malone DA, Jr., Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. *Clin J Sport Med.* 1995; 5:25–31.
121. Uzych L. Anabolic-androgenic steroids and psychiatric-related effects: a review. *Can J Psychiatry.* 1992; 37:23–28.
122. Porcerelli JH, Sandler BA. Anabolic-androgenic steroid abuse and psychopathology. *Psychiatr Clin North Am.* 1998; 21:829–833.
123. Gruber A, Pope HG, Jr. Psychaitric and medical effects of anabolic-androgenic steroid use in women. *Psychother Psychosom.* 2000; 69:19–26.
124. Kanayama G, Cohane GH, Weiss RD, Pope HG. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? *J Clin Psychiatry.* 2003; 64:156–160.
125. Cabasso A. Peliosis hepatis in a young adult bodybuilder. *Med Sci Sports Exerc.* 1994; 26:2–4.
126. Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, Boada LD. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. *Br J Sports Med.* 2005; 39:e27.
127. Kosaka A, Takahashi H, Yajima Y, Tanaka M, Okamura K, Mizumoto R, Katsuta K. Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. *J Gastroenterol.* 1996; 31:450–454.
128. Pavlatos AM, Fultz O, Monberg MJ, Pharmd VA. Review of oxymetholone: a 17alphaalkylated anabolic-androgenic steroid. *Clin Ther.* 2001; 23:789–801; discussion 771.
129. Calof O, Singh AB, Lee MJ, Urban RJ, Kenny AM, Tenover JL, Bhasin S. Adverse events associated with testosterone supplementation of older men. *J Gerontol A Biol Sci Med Sci.* 2005; 60: 1451–1457.
130. Nakao A, Sakagami K, Nakata Y, Komazawa K, Amimoto T, Nakashima K, Isozaki H, Takakura N, Tanaka N. Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. *J Gastroenterol.* 2000; 35:557–562.
131. Gill GV. Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. *Postgrad Med J.* 1998; 74:45–46.
132. MacIndoe JH, Perry PJ, Yates WR, Holman TL, Ellingrod VL, Scott SD. Testosterone suppression of the HPT axis. *J Investig Med.* 1997; 45:441–447.
133. Lloyd FH, Powell P, Murdoch AP. Anabolic steroid abuse by body builders and male subfertility. *BMJ.* 1996; 313:100–101.
134. Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. *Am J Sports Med.* 1990; 18:429–431.
135. Brower KJ. Anabolic steroid abuse and dependence. *Curr Psychiatry Rep.* 2002; 4:377–387.
136. Brower KJ, Blow FC, Young

- JP, Hill EM. Symptoms and correlates of anabolic-androgenic steroid dependence. *Br J Addict.* 1991; 86:759–768.
137. Brower KJ, Eliopoulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. *Am J Psychiatry.* 1990; 147:510–512.
138. Babigian A, Silverman RT. Management of gynecomastia due to use of anabolic steroids in bodybuilders. *Plast Reconstr Surg.* 2001; 107:240–242.
139. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. *N Engl J Med.* 2009; 361(12): 1152–1163
140. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. *Acta Physiol Scand.* 1992; 146:505–510.
141. Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. *J Clin Endocrinol Metab.* 1987; 64:960–963.
142. Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL, Rosenfeld RG. Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both. *J Pediatr.* 1988; 112:210–217.
143. Evans NA, Bowrey DJ, Newman GR. Ultrastructural analysis of ruptured tendon from anabolic steroid users. *Injury.* 1998; 29:769–773.
144. Graham MR, Davies B, Grace FM, Kicman A, Baker JS. Anabolic steroid use: patterns of use and detection of doping. *Sports Med.* 2008; 38:505–525.
145. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. *J Androl.* 2003; 24:299–311.
146. Derman RJ. Effects of sex steroids on women's health: implications for practitioners. *Am J Med.* 1995; 98:137S–143S.
147. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA.* 2006; 295:1288–1299.
148. Casavant MJ, Blake K, Griffith J, Yates A, Copley LM. Consequences of use of anabolic androgenic steroids. *Pediatr Clin North Am.* 2007; 54:677–690, x.
149. Rogol AD. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes. *Curr Opin Pediatr.* 2000; 12:382–387.
150. vandenBerg P, Neumark-Sztainer D, Cafri G, Wall M. Steroid use among adolescents: longitudinal findings from project EAT. *Pediatrics.* 2007; 119:476–486.
151. Jasuja R, Catlin DH, Miller A, Chang YC, Herbst KL, Starcevic B, Artaza JN, Singh R, Datta G, Sarkissian A, Chandsawangbhuwana C, Baker M, Bhasin S. Tetrahydrogestrinone is an androgenic steroid that stimulates androgen receptor-mediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized male rats. *Endocrinology.* 2005; 146:4472–4478.

1. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants and binding proteins. *Endocr Rev.* 1991; 12: 424 – 449.
2. Nindl BC, Kraemer WJ, Marx JO, et al. Growth hormone molecular heterogeneity and exercise. *Exerc Sport Sci Rev.* 2003; 31: 161–166.
3. Lewis UJ, Sinha YN, Lewis GP. Structure and properties of members of the hGH family: a review. *Endocr J.* 2000; 47(Suppl): S1–S8.
4. Arvat E, Ceda GP, Di Vito L, et al. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRP's in human aging. *Pituitary.* 1998; 1: 51–58.
5. Mueller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. *Physiol Rev.* 1999; 79: 511–607.
6. Bowers CY. New insight into the control of growth hormone secretion. In: Kleinberg DL, Clemmons DR, eds. *Central and Peripheral Mechanisms in Pituitary Disease.* Bristol, UK: BioScientifica Ltd; 2002: 163–176.
7. Farhy LS, Straume M, Johnson ML, et al. A construct of interactive feedback control of the GH axis in the male. *Am J Physiol.* 2001; 281: R38–R51.
8. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. *Endocr Rev.* 1998; 19(6): 717–797.
9. Hartman ML. Physiological regulators of growth hormone secretion. In: Juul A, Jorgensen JOL, eds. *Growth Hormone in Adults.* 2nd ed. Cambridge, UK: Cambridge University Press; 2000: 3–53.
10. Kojima M, Hiroshi H, Date Y, et al. Ghrelin is a growth-hormone releasing acylated peptide from stomach. *Nature.* 1999; 402: 656–666.
11. Shuto Y, Shibasaki T, Otagiri A, et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. *J Clin Invest.* 2002; 109: 1429–1436.
12. Veldhuis JD, Bowers CY. Three-peptide control of pulsatile and entropic feedback-sensitive modes of growth hormone secretion: modulation by estrogen and aromatizable androgen. *J Pediatr Endocrinol.* 2003; 16(Suppl. 3): 587–605.
13. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. *Am J Physiol En-*

- ocrinol Metab. 2009; 296: E1085–E1092.
14. Rudman D, Kutner MH, Rogers CM, et al. Impaired growth hormone secretion in the adult population. *J Clin Invest.* 1981; 67: 1361–1369.
 15. Zadik Z, Chalew SA, McCarter RJ, et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. *J Clin Endocrinol Metab.* 1985; 60: 513–516.
 16. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. *J Clin Endocrinol Metab.* 1991; 73: 1081–1088.
 17. Veldhuis JD, Iranmanesh A, Ho KKY, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hypsomatotropism of obesity in man. *J Clin Endocrinol Metab.* 1991; 72: 51–59.
 18. Veldhuis JD, Liem AY, South S, et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. *J Clin Endocrinol Metab.* 1995; 80: 3209–3222.
 19. Iranmanesh A, South S, Liem AY, et al. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men. *Eur J Endocrinol.* 1998; 139: 59–71.
 20. Asplin CM, Faria AC, Carlsen EC, et al. Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. *J Clin Endocrinol Metab.* 1989; 69: 239–245.
 21. Winer LM, Shaw MA, Baumann G. Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. *J Clin Endocrinol Metab.* 1990; 70: 1678–1686.
 22. Weltman A, Weltman JY, Hartman ML, et al. Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. *J Clin Endocrinol Metab.* 1994; 78: 543–548.
 23. van den Berg G, Veldhuis JD, Frolich M, et al. An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. *J Clin Endocrinol Metab.* 1996; 81: 2460–2466.
 24. Clasey JL, Weltman A, Patrie J, et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender and other physiological factors. *J Clin Endocrinol Metab.* 2001; 86: 3845–3852.
 25. Vahl N, Jorgensen JO, Skjaerback, C, et al. Abdominal adiposity rather than age and sex predicts the mass and patterned regularity of growth hormone secretion in mid-life healthy adults. *Am J Physiol.* 1997; 272: E1108–E1116.
 26. Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. *J Clin Endocrinol Metab.* 1997; 82: 727–734.
 27. Franco C, Brandberg J, Lonn L, et al. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. *J Clin Endocrinol Metab.* 2005; 90: 1466–1474.
 28. Colao A, di Somma C, Cuocolo A, et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GHD. *J Clin Endocrinol Metab.* 2001; 86: 1874–1881.
 29. Johannsson G, Grimby G, Sunnerhagen KS, et al. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. *J Clin Endocrinol Metab.* 1997; 82: 2877–2884.
 30. Hartman, ML, Weltman A, Zagar A, et al. Growth hormone replacement therapy in adults with growth hormone deficiency improves maximal oxygen consumption (VO₂ max) independently of dosing regimen or physical activity. *J Clin Endocrinol Metab.* 2008; 93: 125–130.
 31. Lange KH, Larsson B, Flyvbjerg A, et al. Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. *J Clin Endocrinol Metab.* 2002; 87: 4966–4975.
 32. Healy ML, Gibney J, Pentecost C, et al. Effects of high-dose growth hormone on glucose and glycerol metabolism at rest and during exercise in endurance-trained athletes. *J Clin Endocrinol Metab.* 2006; 91: 320–327.
 33. Irving BA, Patrie JT, Anderson SM, et al. The effects of time following acute growth hormone administration on metabolic and power output measurements during acute exercise. *J Clin Endocrinol Metab.* 2004; 89: 4298–4305.
 34. Yarasheski KE, Campbell JA, Smith K, et al. Effect of growth hormone and resistance exercise on muscle growth in young men. *Am J Physiol.* 1992; 262: E261–E267.
 35. Yarasheski KE, Zachweija JJ, Angelopoulos TJ, et al. Short term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. *J Appl Physiol.* 1993; 74: 3073–3076.
 36. Gibney J, Healy ML, Sonksen PH. The growth hormone/insulin-like growth factor-I axis in exercise and sport. *Endocr Rev.* 2007; 28: 608–624.
 37. Ehrnborg C, Rosen T. Physiological and pharmacological basis for the ergogenic effects of growth hormone in elite sports. *Asian J Androl.* 2008; 10: 373–383.
 38. Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. *Ann Intern Med.* 2008; 148: 747–758.
 39. Holt RIG, Sonksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. *Br J Pharmacol.* 2008; 154: 542–556.
 40. Jordi S, Gutierrez-Gallego R, Ventura R, et al. Growth hormone in sport: beyond Beijing 2008. *Ther Drug Monit.* 2009; 31: 3–12.

41. Duchaine D. *Underground Steroid Handbook*. Venice, CA: HLR Technical Books; 1983.
42. Rickert VI, Pawlak-Morello C, Sheppard V, et al. Human growth hormone: a new substance of abuse among adolescents? *Clin Pediatr*. 1992; 31: 723–726.
43. Hanson TK. Pharmacokinetics and acute lipolytic actions of growth hormone: impact of age, body composition, binding proteins, and other hormones. *Growth Horm IGF Res*. 2002; 12: 342–358.
44. Yip RG, Goldman HM. Growth hormone and dexamethasone stimulate lipolysis and activate cyclase in rat adipocytes by selectively shifting Gi a2 to lower density membrane fractions. *Endocrinology*. 1999; 140: 1219–1227.
45. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant GH. *J Clin Endocrinol Metab*. 1993; 76: 309–317.
46. Ehrnborg C, Ellegard L, Bosaeus I, et al. Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults. *Clin Endocrinol*. 2005; 62: 449–467.
47. Berggren A, Ehrnborg C, Rosen T, et al. Short-term administration of supraphysiological recombinant human GH (growth hormone) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. *J Clin Endocrinol Metab*. 2005; 90: 3268–3273.
48. Saugy M, Robinson N, Saudan C, et al. Human growth hormone doping in sport. *Br J Sports Med*. 2006; 40: i35–i39.
49. Guistina A, Barkan A, Chanson P, et al. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. *J Endocrinol Invest*. 2008; 31: 820–838.
50. Bidlingmaier M, Strausburger CJ. Technology insight: detecting growth hormone abuse in athletes. *Nat Clin Pract Endocrinol Metab*. 2007; 3: 769–777.
51. Bidlingmaier M, Suhr J, Ernst A, et al. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. *Clin Chem*. 2009; 55: 445–453.
52. Wideman L, Weltman JY, Patrie JT, et al. Synergy of l-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise. *Am J Physiol Regul Integr Comp Physiol*. 2000; 279: R1467–R1477.

1. Jelkmann W. *Erythropoietin: Molecular Biology and Clinical Use*. Johnson City: FP Graham Publishing, 2003.
2. Cooper CE. The biochemistry of drugs and doping methods used to enhance aerobic sport performance. *Essays Biochem*. 2008; 44:63–83.
3. Lasne F. Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. *J Immunol Methods*. 2001; 253:125–31.
4. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. *Blood*. 2001; 98:3626–34.
5. Jelkmann W. Recombinant EPO production – points the nephrologist should know. *Nephrol Dial Transplant*. 2007; 22:2749–53.
6. Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. *Curr Opin Hematol*. 1998; 5:171–6.
7. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. *Trends Cell Biol*. 2005; 15:146–55.
8. Major A, Mathez-Loic F, Rohling R, et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. *Br J Haematol*. 1997; 98:292–4.
9. Parisotto R, Gore CJ, Emslie KR, et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. *Haematologica*. 2000; 85:564–72.
10. Jelkmann W. Control of erythropoietin gene expression and its use in medicine. *Methods Enzymol*. 2007; 435:179–97.
11. Imagawa S, Yamamoto M, Miura Y. GATA transcription factors negatively regulate erythropoietin gene expression. *Acta Haematol*. 1996; 95:248–56.
12. Warnecke C, Zaborowska Z, Kurreck J, et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. *FASEB J*. 2004; 18:1462–4.
13. Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. *J Clin Invest*. 2007; 117:1068–77.
14. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. *Proc Natl Acad Sci USA*. 1995; 92:5510–4.
15. Bruegge K, Jelkmann W, Metzner E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-1 hydroxylases. *Curr Med Chem*. 2007; 14:1853–62.
16. Milledge JS, Cotes PM. Serum erythropoietin in humans at high altitude and its relation to plasma renin. *J Appl Physiol*. 1985; 59:360–4.
17. Monge C, Leon-Velarde F. Physiological adaptation to high altitude: oxygen transport in mammals and birds. *Physiol Rev*. 1991; 71:1135–72.
18. Favier R, Spielvogel H, Desplanches D, et al. Training in hypoxia vs. training in normoxia in high-altitude natives. *J Appl Physiol*. 1995; 78:2286–93.
19. Levine BD, Stray-Gundersen J. “Living high-training low”: effect of moderate-altitude acclimatization with low-altitude training on performance. *J Appl Physiol*. 1997; 83:102–12.

20. Stray-Gundersen J, Chapman RF, Levine BD. "Living high-training low" altitude training improves sea level performance in male and female elite runners. *J Appl Physiol*. 2001; 91:1113–20.
21. Dainiak N, Spielvogel H, Sorba S, et al. Erythropoietin and the polycythemia of high-altitude dwellers. *Adv Exp Med Biol*. 1989; 271:17–21.
22. Berglund B, Birgegard G, Hemmingsson P. Serum erythropoietin in cross-country skiers. *Med Sci Sports Exerc*. 1988; 20:208–9.
23. Klausen T, Breum L, Fogh-Andersen N, et al. The effect of short and long duration exercise on serum erythropoietin concentrations. *Eur J Appl Physiol Occup Physiol*. 1993; 67:213–7.
24. Ricci G, Masotti M, Paoli-Vitali E, et al. Effects of a mixed physical activity (biathlon) on haematologic parameters, red cell 2,3-DPG and creatine, serum erythropoietin, urinary enzymes and microalbumin. *Eur J Haematol*. 1990; 45:178–9.
25. Schmidt W, Eckardt KU, Hilgendorf A, et al. Effects of maximal and submaximal exercise under normoxic and hypoxic conditions on serum erythropoietin level. *Int J Sports Med*. 1991; 12:457–61.
26. Gareau R, Caron C, Brisson GR. Exercise duration and serum erythropoietin level. *Horm Metab Res*. 1991; 23:355.
27. Ricci G, Masotti M, Paoli-Vitali E, et al. Effects of exercise on haematologic parameters, serum iron, serum ferritin, red cell 2,3-diphosphoglycerate and creatine contents, and serum erythropoietin in long-distance runners during basal training. *Acta Haematol*. 1988; 80:95–8.
28. Schwandt HJ, Heyduck B, Gunga HC, et al. Influence of prolonged physical exercise on the erythropoietin concentration in blood. *Eur J Appl Physiol Occup Physiol*. 1991; 63:463–6.
29. Pagel H, Jelkmann W, Weiss C. A comparison of the effects of renal artery constriction and anemia on the production of erythropoietin. *Pflügers Arch*. 1988; 413:62–6.
30. Roberts D, Smith DJ, Donnelly S, et al. Plasma-volume contraction and exercise-induced hypoxaemia modulate erythropoietin production in healthy humans. *Clin Sci (Lond)*. 2000; 98:39–45.
31. Schobersberger W, Hobisch-Hagen P, Fries P, et al. Increase in immune activation, vascular endothelial growth factor and erythropoietin after an ultramarathon run at moderate altitude. *Immunobiology*. 2000; 201:611–20.
32. Schmidt W, Maassen N, Trost F, et al. Training induced effects on blood volume, erythrocyte turnover and haemoglobin oxygen binding properties. *Eur J Appl Physiol Occup Physiol*. 1988; 57:490–8.
33. Szygula Z. Erythrocytic system under the influence of physical exercise and training. *Sports Med*. 1990; 10:181–97.
34. Park SS, Park J, Ko J, et al. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. *J Pharm Sci*. 2009; 98(5):1688–99.
35. World Health Organization. International nonproprietary names (INN) for biological and biotechnological substances. 2008; http://www.who.int/medicines/services/inn/CompleteBioRevdoc%2008-11-07_2.pdf.
36. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. *Nat Biotechnol*. 2003; 21:414–21.
37. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis stimulating agent for the treatment of anemia. *Curr Hematol Rep*. 2005; 4:436–40.
38. Johnson DL, Farrell FX, Barbone FP, et al. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. *Chem Biol*. 1997; 4:939–50.
39. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. *Blood*. 2006; 108:1830–4.
40. Bouman-Thio E, Franson K, Miller B, et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. *J Clin Pharmacol*. 2008; 48:1197–207.
41. Nakano Y, Imagawa S, Matsumoto K, et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. *Blood*. 2004; 104:4300–7.
42. Imagawa S, Matsumoto K, Horie M, et al. Does K-11706 enhance performance and why? *Int J Sports Med*. 2007; 28:928–33.
43. Safran M, Kim WY, O'Connell F, et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. *Proc Natl Acad Sci USA*. 2006; 103(1):105–10.
44. Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. *Blood*. 2007; 110:2140–7.
45. Kling PJ, Dragsten PR, Roberts RA, et al. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. *Br J Haematol*. 1996; 95:241–8.
46. Ren X, Dorrington KL, Maxwell PH, et al. Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. *J Appl Physiol*. 2000; 89:680–6.
47. Weissbecker L. Die Kobalttherapie. *Dtsch Med Wochenschr*. 1950; 75:116–8.
48. Lippin Y, Dranitzki-Elhalel M, Brill-Almon E, et al. Human erythropoietin gene therapy for patients with chronic renal failure. *Blood*. 2005; 106:2280–6.
49. Gao G, Leberherz C, Weiner DJ, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. *Blood*. 2004; 103:3300–2.
50. Chenuaud P, Larcher T, Rabinowitz JE, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. *Blood*. 2004; 103:3303–4.

51. Gaudard A, Varlet-Marie E, Bressolle F, et al. Drugs for increasing oxygen and their potential use in doping: a review. *Sports Med.* 2003; 33:187–212.
52. Lundby C, Thomsen JJ, Boushel R, et al. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. *J Physiol.* 2007; 578:309–14.
53. Lundby C, Robach P, Boushel R, et al. Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport? *J Appl Physiol.* 2008; 105:581–7.
54. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power in man. *Scand J Med Sci Sports.* 1991; 1:88–93.
55. Audran M, Gareau R, Matecki S, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. *Med Sci Sports Exerc.* 1999; 31:639–45.
56. Birkeland KI, Stray-Gundersen J, Hemmersbach P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. *Med Sci Sports Exerc.* 2000; 32:1238–43.
57. Thomsen JJ, Rentsch RL, Robach P, et al. Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. *Eur J Appl Physiol.* 2007; 101:481–6.
58. Wilkerson DP, Rittweger J, Berger NJ, et al. Influence of recombinant human erythropoietin treatment on pulmonary O₂ uptake kinetics during exercise in humans. *J Physiol.* 2005; 568:639–52.
59. Connes P, Perrey S, Varray A, et al. Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. *Pflügers Arch.* 2003; 447:231–8.
60. Russell G, Gore CJ, Ashenden MJ, et al. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. *Eur J Appl Physiol.* 2002; 86:442–9.
61. Siren AL, Fasshauer T, Bartels C, et al. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. *Neurotherapeutics.* 2009; 6:108–27.
62. Ninot G, Connes P, Caillaud C. Effects of recombinant human erythropoietin injections on physical self in endurance athletes. *J Sports Sci.* 2006; 24:383–91.
63. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. *Nature.* 2000; 405:635.
64. Catlin DH, Breidbach A, Elliott S, et al. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. *Clin Chem.* 2002; 48:2057–9.
65. Pascual JA, Belalcazar V, de Bolos C, et al. Recombinant erythropoietin and analogues: a challenge for doping control. *Ther Drug Monit.* 2004; 26:175–9.
66. Kohler M, Ayotte C, Desharnais P, et al. Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. *Int J Sports Med.* 2008; 29:1–6.
67. Lasne F, Martin L, Crepin N, et al. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. *Anal Biochem.* 2002; 311:119–26.
68. Lasne F, Martin L, Martin J, et al. Isoelectric profiles of human erythropoietin are different in serum and urine. *Int J Biol Macromol.* 2007; 41:354–7.
69. Sytkowski AJ, Fisher JW. Isolation and characterization of an anti-peptide monoclonal antibody to human erythropoietin. *J Biol Chem.* 1985; 260:14727–31.
70. WADA. Harmonization of the method for the identification of Epoetin alfa and beta (EPO) and Darbepoetin alfa (NESP) by IEF-double blotting and chemiluminescent detection. 2007; www.wada-ama.org/rtecontent/document/td2007epo_en.pdf.
71. Schellekens H. Biosimilar epoetins: how similar are they? *Eur J Hosp Pharm.* 2004; 3:43–47.
72. Jelkmann W. Erythropoiesis stimulating agents and techniques: a challenge for doping analysts. *Curr Med Chem.* 2009; 16(10):1236–47.
73. Ashenden M, Varlet-Marie E, Lasne F, et al. The effects of microdose recombinant human erythropoietin regimens in athletes. *Haematologica.* 2006; 91:1143–4.
74. Breidbach A, Catlin DH, Green GA, et al. Detection of recombinant human erythropoietin in urine by isoelectric focusing. *Clin Chem.* 2003; 49:901–7.
75. Lamon S, Robinson N, Mangin P, et al. Detection window of Darbepoetin-alpha following one single subcutaneous injection. *Clin Chim Acta.* 2007; 379:145–9.
76. Morkeberg J, Lundby C, Nissen-Lie G, et al. Detection of darbepoetin alfa misuse in urine and blood: a preliminary investigation. *Med Sci Sports Exerc.* 2007; 39:1742–7.

1. Almquist J, Valovich McLeod TC, Cavanna A, Jenkinson D, Lincoln AE, Loud K, et al. Summary statement: appropriate medical care for the secondary school-aged athlete. *J Athl Train.* 2008;43:416–427.
2. Maughan RJ. Nutritional ergogenic aids and exercise performance. *Nutr Res Rev.* 1999;12:255–280.
3. Maughan RJ, King DS, Trevor L. Dietary supplements. *J Sports Sci.* 2004;22:95–113.
4. Volpe SL. Micronutrient requirements for athletes. *Clin Sports Med.* 2007;26:119–130.
5. Striegel H, Simon P, Wurster C, et al. The use of nutritional supplements among master athletes. *Int J Sports Med.* 2006;27:236–241.
6. Isidori A, Lo Monaco A, Cappa M. A study of growth hormone release in men after administration of amino acids. *Curr Med Res Opin.* 1981;7:475–481.
7. Alba RJ, Albrecht Muller O. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. *J Clin Endocrinol Metab.* 1988;67:1186–1189.
8. Williams MH, Leutholtz BC. Nutritional ergogenic aids. In: Maughan R, ed. *Nutrition in sport.* Oxford: Blackwell Science; 2000:356–366.
9. Phillips SM. Dietary protein for athletes: from requirements to metabolic advantage. *Appl Physiol Nutr Metab.* 2006;31:647–654.
10. Boisseau N, Vermorel M, Rance M, Duché P, Patureau-Mirand P. Protein requirements in male adolescent soccer players. *Eur J Appl Physiol.* 2007;100:27–33.
11. Nemet D, Eliakim A. Pediatric sport nutrition – an update. *Curr Opin Clin Nutr Metab Care.* 2009;12:304–309.
12. Carli G, Bonifazi M, Lodi L. Changes in the exercise induced hormone response to branched chain amino acids administration. *Eur J Appl Physiol.* 1992;64:272–277.
13. Hicks TP, Conti F. Amino acids as the source of considerable excitation in cerebral cortex. *Can J Physiol Pharmacol.* 1996;74:341–361.
14. Blomstrand E, Celsing F, Newsholme EA. Changes in plasma concentrations of aromatic and branched-chain amino acid during sustained exercise in men and their possible role in fatigue. *Acta Physiol Scand.* 1988;133:115–121.
15. Carli G, Bonifazi M, Lodi L, et al. Changes in the exercise induced hormone response to branched chain amino acids administration. *Eur J Appl Physiol.* 1992;64:272–277.
16. Di Luigi L, Pigozzi F, Casini A, et al. Effects of prolonged amino acid supplementations on hormonal secretion in male athletes. *Med Sport.* 1994;47:529–539.
17. Evain-Brion D, Donnadieu M, Roger M, et al. Simultaneous study of somatotrophic and corticotrophic pituitary secretion during ornithine infusion test. *Clin Endocrinol.* 1982;17:119–122.
18. Tegelman R, Johansson C, Hemmingsson P, Eklöf R, Carlström K, Pousette A. Endogenous anabolic and catabolic steroids hormones in male and female athletes during off season. *Int J Sports Med.* 1990;11:103–106.
19. Dolinska M, Albrecht J. Glutamate uptake is inhibited by L-arginine in mitochondria isolated from rat cerebrum. *Neuroreport.* 1997;8:2365–2368.
20. Brass EP. Carnitine and sports medicine: use or abuse? *Ann N Y Acad Sci.* 2004;1033: 67–78.
21. Broad EM, Maughan RJ, Galloway SD. Carbohydrate, protein, and fat metabolism during exercise after oral carnitine supplementation in humans. *J Sport Nutr Exerc Metab.* 2008;18: 567–584.
22. Smith WA, Fry AC, Tschume LC, Bloomer RJ. Effect of glycine propionyl-L-carnitine on aerobic and anaerobic exercise performance. *Int J Sport Nutr Exerc Metab.* 2008;18:19–36.
23. Dillard CJ, Litov RE, Savin WM, Dumelin EE, Tappel AL. Effects of exercise, vitamin E, and ozone on pulmonary function and lipid peroxidation. *J Appl Physiol.* 1978;45(6):927–932.
24. Jackson MJ. Exercise and oxygen radical production by muscle. In: Sen CK, Packer L, Hanninen O, eds. *Handbook of oxidants and antioxidants in exercise.* Amsterdam: Elsevier Science 2000:57–68.
25. Halliwell B. Oxygen radicals: a commonsense look at their nature and medical importance. *Med Biol.* 1984;62(2):71–77.
26. Reid MB. Nitric oxide, reactive oxygen species, and skeletal muscle contraction. *Med Sci Sports Exerc.* 2001;33(3):371–376.
27. Goldhaber JI, Qayyum MS. Oxygen free radicals and excitation–contraction coupling. *Antioxid Redox Signal.* 2000;2(1):55–64.
28. Halliwell B, Cross CE. Oxygen-derived species: their relation to human disease and environmental stress. *Environ Health Perspect* 1994;102(Suppl 10):5–12.
29. Aruoma OI. Free radicals and antioxidant strategies in sport. *J Nutr Biochem.* 1994;5: 370–381.
30. Ji LL. Oxidative stress during exercise: implication of antioxidant nutrients. *Free Radic Biol Med.* 1995;18:1079–1086.
31. Tiidus PM, Houston ME. Vitamin E status and response to exercise training. *Sports Med.* 1995;20:12–23.
32. Clarkson PM. Antioxidants and physical performance. *Clin Rev Food Sci Nutr.* 1995;35: 131–141.
33. Maxwell SRJ. Prospects for the use of antioxidant therapies. *Drugs.* 1995;49:345–361.
34. Sen CK. Oxidants and antioxidants in exercise. *J Appl Physiol.* 1995;675:79–86.
35. Dekkers JC, van Doornen LJP, Kemper HCG. The role of antioxidant vitamins and enzymes in the prevention of exercise-induced muscle damage. *Sports Med.* 1996;21:213–238. 36. Packer L. Oxidants, antioxidant nutrients and the athlete. *J Sports Sci.* 1997;15:353–363.
37. Ashton T, Rowlands CC, Jones E, et al. Electron spin resonance spectroscopic detection of oxygen-centered radicals in human serum following exhaustive exercise. *Eur J Appl Physiol.* 1998;77:498–502.
38. Kanter M. Free radicals, exercise and antioxidant supplementation. *Proc Nutr Soc.* 1998;57:9–13.

39. Urso ML, Clarkson PM. Oxidative stress, exercise, and antioxidant supplementation. *Toxicology*. 2003;189(1–2):41–54.
40. Watson TA, Callister R, Taylor RD, Sibbritt DW, MacDonald-Wicks LK, Garg ML. Antioxidant restriction and oxidative stress in short-duration exhaustive exercise. *Med Sci Sports Exerc*. 2005;37(1):63–71.
41. Knez WL, Coombes JS, Jenkins DG. Ultra-endurance exercise and oxidative damage: implications for cardiovascular health. *Sports Med*. 2006;36(5):429–441.
42. Sauberlich HE. Ascorbic acid. In: Brown ML, ed. *Present knowledge in nutrition*. Washington, DC: International Life Sciences Institute; 1990:132–141.
43. Olson JA, Vitamin A. In: Brown ML, ed. *Present knowledge in nutrition*. Washington, DC: International Life Sciences Institute; 1990:96–107.
44. Fisher-Wellman K, Bloomer RJ. Acute exercise and oxidative stress: a 30 year history. *Dynamic Medicine*. 2009;8:1–25.
45. vanSomeren KA, Edwards AJ, Howatson G. Supplementation with beta-hydroxy-beta-methylbutyrate (HMB) and alpha-ketoglutaric acid (KIC) reduces signs and symptoms of exercise-induced muscle damage in man. *Int J Sport Nutr Exerc Metab*. 2005;15(4):413–424.
46. Nissen S, Sharp R, Ray M, Rathmacher JA, Rice D, Fuller JC Jr. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. *J Appl Physiol*. 1996;81:2095–2104.
47. Nitter AE, Panton L, Rathmacher JA, Petersen A, Sharp R. Effects of beta-hydroxy-beta-methylbutyrate on muscle damage after a prolonged run. *J Appl Physiol*. 2000;89(4): 1340–1344.
48. Jowko E, Ostaszewski P, Jank M, Sacharuk J, Zieniewicz A, Wilczak J. Creatine and beta-hydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. *Nutrition*. 2001;17:558–566.
49. Wilson GJ, Wilson JM, Manninen AH. Effects of beta-hydroxy-beta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex, and training experience: a review. *Nutr Metab*. 2008;5:1.
50. Gallagher PM, Carrithers JA, Godard MP, Schulze KE, Trappe SW. Beta-hydroxy-beta-methylbutyrate ingestion, part I: effects on strength and fat free mass. *Med Sci Sports Exerc*. 2000; 32:2109–2115.
51. Vukovich MD, Stubbs NB, Bohlken RM. Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. *J Nutr*. 2001;131: 2049–2052.
52. Panton LB, Rathmacher JA, Baier S, Nissen S. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. *Nutrition*. 2000;16:734–739.
53. Neighbors KL, Ransone JW, Jacobson BH, LeFavi RG. Effects of dietary beta-hydroxy-beta-methylbutyrate on body composition in collegiate football players. *Med Sci Sports Exerc*. 2000;32:S60.

1. World Anti-Doping Agency. *The 2009 Prohibited List*. Vol. 2009: World Anti-Doping Agency, 2008.
2. World Anti-Doping Agency. *Adverse Analytical Findings Reported by Accredited Laboratories*. Vol. 2008.
3. Schänzer W, Geyer H, Donike M. Metabolism of metandienone in man – identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas-chromatographic mass-spectrometric identification of bis-hydroxylated metabolites. *Journal of Steroid Biochemistry and Molecular Biology*. 1991; 38:441–464.
4. Schänzer W, Opfermann G, Donike M. Metabolism of stanozolol – identification and synthesis of urinary metabolites. *Journal of Steroid Biochemistry and Molecular Biology*. 1990; 36:153–174.
5. Schänzer W, Horning S, Donike M. Metabolism of anabolic-steroids in humans - synthesis of 6-beta-hydroxy metabolites of 4-chloro-1,2-dehydro-17-alpha-methyltestosterone, fluoxymesterone, and metandienone. *Steroids*. 1995; 60:353–366.
6. Schänzer W, Horning S, Opfermann G, Donike M. Gas chromatography mass spectrometry identification of long-term excreted metabolites of the anabolic steroid 4-chloro-1,2-dehydro-17 alpha-methyltestosterone in humans. *Journal of Steroid Biochemistry and Molecular Biology*. 1996; 57:363–376.
7. Parr MK, Geyer H, Gütschow M, et al. *New Steroids on the “Supplement” Market*. Köln: 26th Cologne Workshop on Doping Analysis, 2008.
8. Sobolevsky T, Virus E, Semenistaya E, Kachala V, Kachala I, Rodchenkov G. *Orastan-A: Structural Elucidation and Detection in Urine*. Köln: 26th Cologne Workshop on Doping Analysis, 2008.
9. Rodchenkov G, Sobolevsky T, Sizoi V. *New designer anabolic steroids from internet*. In: Schänzer W, Geyer H, Gotzmann A, Mareck U, eds. *Recent Advances in Doping Analysis (14)*. Köln: Sport und Buch Strauß, 2006:141–150.
10. Kazlauskas R. *Miscellaneous projects in sports drug testing at the National Measurement Institute, Australia, 2005*. In: Schänzer W, Geyer H, Gotzmann A, Mareck U, eds. *Recent Advances in Doping Analysis (14)*. Köln: Sport und Buch Strauß, 2006:129–140.
11. Schänzer W, Opfermann G, Donike M. 17-Epimerization of 17-alpha-methyl anabolic-steroids in humans – metabolism and synthesis of 17-alpha-hydroxy-17-beta-methyl steroids. *Steroids*. 1992; 57:537–550.
12. Kleemann A, Roth HJ. *Arzneistoffgewinnung: Naturstoffe und Derivate*. Stuttgart: Thieme, 1983.
13. Schänzer W. *Metabolism of anabolic androgenic steroids*. *Clinical Chemistry*. 1996; 42: 1001–1020.
14. Becchi M, Aguilera R, Farizon Y, Flament M, Casabianca H, James P. *Gas chromatography/ combustion/isotope-ratio mass spectrometry analysis of urinary steroids to detect misuse of testosterone in sport*. *Rapid Communications in Mass Spectrometry*.

- 1994; 8:304–308.
15. Aguilera R, Hatton C, Catlin D. Detection of epitestosterone doping by isotope ratio mass spectrometry. *Clinical Chemistry*. 2002; 48:629–636.
 16. Aguilera R, Becchi M, Casabianca H, et al. Improved method of detection of testosterone abuse by gas chromatography/combustion/isotope ratio mass spectrometry analysis of urinary steroids. *Journal of Mass Spectrometry*. 1996; 31:169–176.
 17. Aguilera R, Becchi M, Grenot C, Casabianca H, Hatton C. Detection of testosterone misuse: comparison of two chromatographic sample preparation methods for gas chromatographic– combustion/isotope ratio mass spectrometric analysis. *Journal of Chromatography B*. 1996; 687:43–53.
 18. Aguilera R, Chapman T, Catlin D. A rapid screening assay for measuring urinary androsterone and etiocholanolone d13C values by gas chromatography/combustion/isotope ratio mass spectrometry. *Rapid Communications in Mass Spectrometry*. 2000; 14:2294–2299.
 19. Aguilera R, Chapman T, Starcevic B, Hatton C, Catlin D. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. *Clinical Chemistry*. 2001; 47:292–300.
 20. Vogel J. *Fractionation of the Carbon Isotopes During Photosynthesis*. Berlin: Springer-Verlag, 1980.
 21. O'Leary M. Carbon isotope fractionation in plants. *Phytochemistry*. 1981; 20:553–567.
 22. Donike M. *N*-methyl-*N*-trimethylsilyl-trifluoroacetamide a new silylating agent from series of silylated amides. *Journal of Chromatography*. 1969; 42:103–104.
 23. Schänzer W. *Analytik von Dopingsubstanzen – Derivatisierung*. Vol. 2009: Institut für Biochemie, Deutsche Sporthochschule Köln, 2001.
 24. Donike M, Zimmermann J. Preparation of trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl enol ethers from ketosteroids for investigations by gas-chromatography and mass-spectrometry. *Journal of Chromatography*. 1980; 202:483–486.
 25. Geyer H, Schänzer W, Mareck-Engelke U, Nolteernsting E, Opfermann G. Screening procedure for anabolic steroids – control of hydrolysis with deuterated androsterone glucuronide and studies with direct hydrolysis. In: Mareck-Engelke U, ed. *Recent Advances in Doping Analysis (5)*. Köln: Sport und Buch Strauss, 1998:99–102.
 26. Flenker U, Horning S, Nolteernsting E, Geyer H, Schänzer W. Measurement of 13C/12C-ratios to confirm misuse of endogenous steroids. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. *Recent Advances in Doping Analysis (6)*. Köln: Sport und Buch Strauss, 1999:243–256.
 27. Flenker U, Güntner U, Schänzer W. Delta C-13-values of endogenous urinary steroids. *Steroids*. 2008; 73:408–416.
 28. Piper T, Mareck U, Geyer H, et al. Determination of C-13/C-12 ratios of endogenous urinary steroids: method validation, reference population and application to doping control purposes. *Rapid Communications in Mass Spectrometry*. 2008; 22:2161–2175.
 29. Docherty G, Jones V, Evershed R. Practical and theoretical considerations in the gas chromatography/ combustion/isotope ratio mass spectrometry d13C analysis of small polyfunctional compounds. *Rapid Communications in Mass Spectrometry*. 2001; 15:730–738.
 30. World Anti-Doping Agency. WADA Technical Document TD2009MRPL. Vol. 2009: World Anti-Doping Agency, 2008.
 31. World Anti-Doping Agency. WADA Technical Document TD2003IDCR. Vol. 2009: World Anti-Doping Agency, 2004.
 32. Schänzer W, Donike M. Metabolism of anabolic-steroids in man – synthesis and use of reference substances for identification of anabolic-steroid metabolites. *Analytica Chimica Acta*. 1993; 275:23–48.
 33. Geyer H, Parr MK, Koehler K, Mareck U, Schanzer W, Thevis M. Nutritional supplements cross-contaminated and faked with doping substances. *Journal of Mass Spectrometry*. 2008; 43:892–902.
 34. US Drug Enforcement Administration. *Anabolic Steroids Control Act*. Vol. 2005: US Drug Enforcement Administration, 2004.
 35. Parr MK, Kazlauskas R, Schlörer N, et al. 6 alpha-Methylandrosterone: gas chromatographic mass spectrometric detection in doping control. *Rapid Communications in Mass Spectrometry*. 2008; 22:321–329.
 36. Parr MK, Fußhöller G, Schlörer N, et al. Metabolism of androsta-1,4,6-triene-3,17-dione and detection by gas chromatography/ mass spectrometry in doping control. *Rapid Communications in Mass Spectrometry*. 2009; 23:207–218.
 37. Thevis M, Schanzer W. Mass spectrometry in sports drug testing: Structure characterization and analytical assays. *Mass Spectrometry Reviews*. 2007; 26:79–107.
 38. Thevis M, Geyer H, Mareck U, Schänzer W. Screening for unknown synthetic steroids in human urine by liquid chromatography–tandem mass spectrometry. *Journal of Mass Spectrometry*. 2005; 40:955–962.
 39. Pozo OJ, Deventer K, Eeno PV, Delbeke FT. Efficient approach for the comprehensive detection of unknown anabolic steroids and metabolites in human urine by liquid chromatography– electrospray–tandem mass spectrometry. *Analytical Chemistry*. 2008; 80:1709–1720.
 40. World Anti-Doping Agency. WADA Technical Document TD2004EAAS. Vol. 2007: World Anti-Doping Agency, 2004.
 41. Donike M, Barwald KR, Klostermann K, Schanzer W, Zimmermann J. The detection of exogenous testosterone. *International Journal of Sports Medicine*. 1983; 4:68.
 42. Geyer H. Die gas-chromatographisch/massenspektrometrische Bestimmung von Steroidprofilen im Urin von Athleten, Institute of Biochemistry. Köln: German Sport University, 1986.
 43. Mareck-Engelke U, Geyer H, Donike M. Stability of steroid profiles. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, Rauth S, eds. *10th Cologne Workshop on Dope Analysis*. Köln: Sport und Buch Strauss, 1992:87–89.

44. Mareck-Engelke U, Geyer H, Donike M. Stability of steroid profiles (2): excretion rates from morning urines. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, Rauth S, eds. *Recent Advances in Doping Analysis*. Köln: Sport und Buch Strauss, 1993:85.
45. Mareck-Engelke U, Geyer H, Donike M. Stability of steroid profiles (4): the circadian rhythm of urinary ratios and excretion rates of endogenous steroids in female and its menstrual dependency. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, eds. *Recent Advances in Doping Analysis (2)*. Köln: Sport und Buch Strauss, 1994:135.
46. Mareck-Engelke U, Geyer H, Donike M. Stability of steroid profiles (3): the circadian rhythm of urinary ratios and excretion rates of endogenous steroids in male. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, eds. *Recent Advances in Doping Analysis (2)*. Köln: Sport und Buch Strauss, 1994:121.
47. Mareck-Engelke U, Geyer H, Donike M. Stability of steroid profiles (5): the annual rhythm of urinary ratios and excretion rates of endogenous steroids in female and its menstrual dependency. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, eds. *Recent Advances in Doping Analysis (3)*. Köln: Sport und Buch Strauss, 1995:177.
48. Nitschke R. Steroidprofile und Veränderungen biochemischer Parameter bei Hochleistungsradrennfahrern während zwei Rundfahrten, Institute of Biochemistry. Köln: German Sport University, 1996.
49. Dehennin L, Matsumoto AM. Long-term administration of testosterone enanthate to normal men: alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport. *Journal of Steroid Biochemistry and Molecular Biology*. 1993; 44:179–189.
50. Donike M, Ueki M, Kuroda Y, et al. Detection of dihydrotestosterone (DHT) doping: alterations in the steroid profile and reference ranges for DHT and its 5 α -metabolites. *Journal of Sports Medicine and Physical Fitness*. 1995; 35:235–250.
51. Thevis M, Geyer H, Mareck U, Flenker U, Schanzer W. Doping-control analysis of the 5 α reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite. *Therapeutic Drug Monitoring*. 2007; 29:236–247.
52. Bowers LD. Oral dehydroepiandrosterone supplementation can increase the testosterone/ epitestosterone ratio. *Clinical Chemistry*. 1999; 45:295–297.
53. Uralets VP, Gillette PA. Over-the-counter anabolic steroids 3-androsten-3,17-dione; 4-androsten-3 beta,17 beta-diol; and 19-nor-4-androsten-3,17-dione: excretion studies in men. *Journal of Analytical Toxicology*. 1999; 23:357–366.
54. Dehennin L, Ferry M, Lafarge P, Peres G, Lafarge JP. Oral administration of dehydroepiandrosterone to healthy men: alteration of the urinary androgen profile and consequences for the detection of abuse in sport by gas chromatography–mass spectrometry. *Steroids*. 1998; 63:80–87.
55. Geyer H, Schänzer W, Mareck-Engelke U, Donike M. Factors influencing the steroid profile. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, eds. *Recent Advances in Doping Analysis (3)*. Köln: Sport und Buch Strauss, 1995:95–113.
56. De Laeter J, Kurz M. Alfred Nier and the sector field mass spectrometer. *Journal of Mass Spectrometry*. 2006; 41:847–854.
57. Habfast K. Advanced isotope ratio mass spectrometry I: magnetic isotope ratio mass spectrometers. In: Platzner I, ed. *Modern Isotope Ratio Mass Spectrometry*, Vol. 145. *Chemical Analysis*. Chichester: John Wiley & Sons Ltd, 1997:11–82.
58. Barrie A, Bricout J, Koziet J. Gas chromatography-stable isotope ratio analysis at natural abundance levels. *Biomedical Mass Spectrometry*. 1984; 11:583–588.
59. Brand W. High precision isotope ratio monitoring techniques in mass spectrometry. *Journal of Mass Spectrometry*. 1996; 31:225–235.
60. Flenker U, Hebestreit M, Piper T, Hülsemann F, Schänzer W. Improved performance and maintenance in gas chromatography/ isotope ratio mass spectrometry by precolumn solvent removal. *Analytical Chemistry*. 2007; 79:4162–4168.
61. Sacks G, Zhang Y, Brenna J. Fast gas chromatography combustion isotope ratio mass spectrometry. *Analytical Chemistry*. 2007; 79:6348–6358.
62. Tobias H, Sacks G, Zhang Y, Brenna J. Comprehensive two-dimensional gas chromatography combustion isotope ratio mass spectrometry. *Analytical Chemistry*. 2008; 80:8613–8621.

1. Baumann G. Growth hormone heterogeneity: Genes, isohormones, variants, and binding proteins. *Endocr Rev*. 1991; 12:424–49
2. Hirt H, Kimelman J, Birnbaum MJ, Chen EY, Seeburg PH, Eberhardt NL, Barta A. The human growth hormone gene locus: Structure, evolution, and allelic variations. *DNA*. 1987; 6:59–70
3. Igout A, Van Beeumen J, Frankenne F, Scippo ML, Devreese B, Hennen G. Purification and biochemical characterization of recombinant human placental growth hormone produced in *Escherichia coli*. *Biochem J*. 1993; 295:719–24
4. Cooke NE, Ray J, Watson MA, Estes PA, Kuo BA, Liebhaber SA. Human growth hormone gene and the highly homologous growth hormone variant gene display different splicing patterns. *J Clin Invest*. 1988; 82:270–5
5. Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson L, Boguszewski CL, Hay J, Healy ML, Napoli R, Dall R, Rosen T, Strasburger CJ. The response of molecular isoforms of growth hormone to acute exercise in trained adult males. *J Clin Endocrinol Metab*. 2001; 86:200–6
6. Nindl BC. Exercise modulation of growth hormone isoforms: Current knowledge and future directions for the exercise endocrinologist. *Br J Sports Med*. 2007; 41:346–8; discussion 348

7. Baumann G. Growth hormone heterogeneity in human pituitary and plasma. *Horm Res.* 1999; 51:2–6
8. Popii V, Baumann G. Laboratory measurement of growth hormone. *Clin Chim Acta.* 2004; 350:1–16
9. Baumann G, Stolar MW, Buchanan TA. The metabolic clearance, distribution, and degradation of dimeric and monomeric growth hormone (GH): Implications for the pattern of circulating GH forms. *Endocrinology.* 1986;119:1497–501
10. Baumann G, Amburn K, Shaw MA. The circulating growth hormone (GH)-binding protein complex: A major constituent of plasma GH in man. *Endocrinology.* 1988; 122:976–84
11. Kratzsch J, Selisko T, Birkenmeier G. Identification of transformed alpha 2-macroglobulin as a growth hormone-binding protein in human blood. *J Clin Endocrinol Metab.* 1995; 80: 585–90
12. Bidlingmaier M, Freda PU. Measurement of human growth hormone by immunoassays: Current status, unsolved problems and clinical consequences. *Growth Horm IGF Res.* 2010; 20:19–25
13. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. *Clin Endocrinol (Oxf).* 2007; 67:65–70
14. Wieringa GE, Trainer PJ. Commentary: Harmonizing growth hormone measurements: Learning lessons for the future. *J Clin Endocrinol Metab.* 2007; 92:2874–5
15. Boguszewski CL, Hynsjo L, Johannsson G, Bengtsson BA, Carlsson LM. 22-kD growth hormone exclusion assay: A new approach to measurement of non-22-kD growth hormone isoforms in human blood. *Eur J Endocrinol.* 1996; 135:573–82
16. Wada M, Uchida H, Ikeda M, Tsunekawa B, Naito N, Banba S, Tanaka E, Hashimoto Y, Honjo M. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma. *Mol Endocrinol.* 1998; 12:146–56
17. Keller A, Wu Z, Kratzsch J, Keller E, Blum WF, Kniess A, Preiss R, Teichert J, Strasburger CJ, Bidlingmaier M. Pharmacokinetics and pharmacodynamics of GH: Dependence on route and dosage of administration. *Eur J Endocrinol.* 2007; 156:647–53
18. Ishikawa M, Yokoya S, Tachibana K, Hasegawa Y, Yasuda T, Tokuhiko E, Hashimoto Y, Tanaka T. Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children. *J Clin Endocrinol Metab.* 1999; 84:98–104
19. Leung KC, Howe C, Gui LY, Trout G, Veldhuis JD, Ho KK. Physiological and pharmacological regulation of 20-kDa growth hormone. *Am J Physiol Endocrinol Metab.* 2002; 283: E836–43
20. Tsushima T, Katoh Y, Miyachi Y, Chihara K, Teramoto A, Irie M, Hashimoto Y. Serum concentration of 20K human growth hormone (20K hGH) measured by a specific enzymelinked immunosorbent assay. Study Group of 20K hGH. *J Clin Endocrinol Metab.* 1999; 84:317–22
21. Sinha YN, Jacobsen BP. Human growth hormone (hGH)-(44-191), a reportedly diabetogenic fragment of hGH, circulates in human blood: Measurement by radioimmunoassay. *J Clin Endocrinol Metab.* 1994; 78:1411–8
22. Wu Z, Bidlingmaier M, Friess SC, Kirk SE, Buchinger P, Schiessl B, Strasburger CJ. A new nonisotopic, highly sensitive assay for the measurement of human placental growth hormone: Development and clinical implications. *J Clin Endocrinol Metab.* 2003; 88:804–11
23. Celniker AC, Chen AB, Wert RM, Jr., Sherman BM. Variability in the quantitation of circulating growth hormone using commercial immunoassays. *J Clin Endocrinol Metab.* 1989;68: 469–76
24. Bidlingmaier M, Suhr J, Ernst A, Wu Z, Keller A, Strasburger CJ, Bergmann A. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. *Clin Chem.* 2009; 55:445–53
25. Hayakawa M, Shimazaki Y, Tsushima T, Kato Y, Takano K, Chihara K, Shimatsu A, Irie M. Metabolic effects of 20-kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: Results of an exploratory uncontrolled multi-center clinical trial of 20KhGH. *J Clin Endocrinol Metab.* 2004; 89:1562–71
26. Bidlingmaier M, Strasburger CJ. Technology insight: Detecting growth hormone abuse in athletes. *Nat Clin Pract Endocrinol Metab.* 2007; 3:769–77
27. Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. *Baillieres Best Pract Res Clin Endocrinol Metab.* 2000;14:99–109
28. Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of doping with human growth hormone. *Lancet.* 1999; 353:895
29. Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson L, Boguszewski CL, Hay J, Boroujerdi M, Cittadini A, Dall R, Rosen T, Strasburger CJ. Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males. *J Clin Endocrinol Metab.* 2001; 86:1731–7
30. Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P. Human growth hormone doping in sport. *Br J Sports Med.* 2006; 40 Suppl 1:i35–9
31. Gutierrez-Gallego R, Bosch J, Such-Sanmartin G, Segura J. Surface plasmon resonance immuno assays – A perspective. *Growth Horm IGF Res.* 2009; 19:388–98
32. Kohler M, Puschel K, Sakharov D, Tonevitskiy A, Schanzer W, Thevis M. Detection of recombinant growth hormone in human plasma by a 2-D PAGE method. *Electrophoresis.* 2008; 29:4495–502
33. Kohler M, Thomas A, Puschel K, Schanzer W, Thevis M. Identification of human pituitary growth hormone variants by mass spectrometry. *J Proteome Res.* 2009; 8:1071–6
34. Segura J, Gutierrez-Gallego R, Ventura R, Pascual JA, Bosch J, Such-Sanmartin G, Nikolovski Z, Pinyot A, Pichini S. Growth hormone in sport: Beyond Beijing 2008. *Ther Drug Monit.* 2009; 31:3–13

1. Jelkmann W. Erythropoietin after a century of research: younger than ever. *Eur J Haematol.* 2007; 78: 183–205.
2. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamics and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. *Drugs.* 1989; 38: 863–899.
3. Lappin TR, Rich IN. Erythropoietin – the first 90 years. *Clin Lab Haematol.* 1996; 18: 137–145.
4. Lacombe C, Mayeux P. Biology of erythropoietin. *Haematologica.* 1998; 83: 724–732.
5. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. *JAMA.* 2005; 293: 90–95.
6. Badia R, de la Torre R, Segura J. Erythropoietin: potential abuse in sport and possible methods for its detection. *Biol Clin Haematol.* 1992; 14: 177–184.
7. Pascual JA, Belalcazar V, de Bolos C, Gutierrez R, Llop E, Segura J. Recombinant erythropoietin and analogues: a challenge for doping control. *Ther Drug Monit.* 2004; 26: 175–179.
8. Peltre G, Thormann W. Evaluation report of the EPO blood tests. Independent internal Review to the World Antidoping Agency. 2003; 1–5.
9. Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart MT, Marion B, Bressolle F. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. *Med Sci Sports Exerc.* 1999; 31: 639–645.
10. Breyman C. Erythropoietin test methods. *Baillieres Best Pract Res Clin Endocrinol Metab.* 2000; 14: 135–145.
11. Magnani M, Corsi D, Bianchi M, Paiardini M, Galluzzi L, Gargiullo E, Parisi A, Pigozzi F. Identification of blood erythroid markers useful in revealing erythropoietin abuse in athletes. *Blood Cells Mol Dis.* 2001; 27: 559–571.
12. Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Bruognara C, Howe C, Martin DT, Trout GJ, Hahn AG. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. *Haematologica.* 2000; 85: 564–572.
13. Parisotto R, Wu M, Ashenden MJ, Emslie KR, Gore CJ, Howe C, Kazlauskas R, Sharpe K, Trout GJ, Xie M. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. *Haematologica.* 2001; 86: 128–137.
14. Gore CJ, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Hahn AG. Second-generation blood tests to detect erythropoietin abuse by athletes. *Haematologica.* 2003; 88: 333–344.
15. Banfi G. Reticulocytes in sports medicine. *Sports Med.* 2008; 38: 187–211.
16. Abellan R, Ventura R, Remacha AF, Rodríguez FA, Pascual JA, Segura J. Intermittent hypoxia exposure in hypobaric chamber and EPO abuse Interpretation. *J Sports Sci.* 2007; 25: 1241–1250.
17. Robinson N, Sottas PE, Mangin P, Saugy M. Bayesian detection of abnormal hematological values to introduce a no-start rule for heterogeneous populations of athletes. *Haematologica.* 2007; 92: 1143–1144.
18. Sharpe K, Ashenden MJ, Schumacher YO. A third generation approach to detect erythropoietin abuse in athletes. *Haematologica.* 2006; 91: 356–363.
19. Morkeberg J, Saltin B, Belhage B, Damsgaard R. Blood profiles in elite cross-country skiers: a 6-year follow-up. *Scand J Med Sci Sports.* 2008; 19: 198–205.
20. Appolonova SA, Dikunets MA, Rodchenkov GM. Possible indirect detection of rHuEPO administration in human urine by high-performance liquid chromatography tandem mass spectrometry. *Eur J Mass Spectrom (Chichester, Eng).* 2008; 14: 201–209.
21. Robinson Y, Cristancho E, Boning D. Erythrocyte aspartate aminotransferase activity as a possible indirect marker for stimulated erythropoiesis in male and female athletes. *Lab Hematol.* 2007; 13: 49–55.
22. Borrione P, Parisi A, Salvo RA, Spaccamiglio A, Pautasso M, Baraban D, Piccoli GB, Pigozzi F, Angeli A. A peculiar pattern of expression of the transferrin receptor (CD71) by reticulocytes in patients given recombinant human erythropoietin (rHuEPO): a novel marker for abuse in sport? *J Biol Regul Homeost Agents.* 2007; 21: 79–88.
23. Varlet-Marie E, Audran M, Lejeune M, Bonafoux B, Sicart MT, Marti J, Piquemal D, Commes T. Analysis of human reticulocyte genes reveals altered erythropoiesis: potential use to detect recombinant human erythropoietin doping. *Haematologica.* 2004; 89: 991–997.
24. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. *Adv Chronic Kidney Dis.* 2009; 16: 117–130.
25. Kochendoerfer GG, Chen SY, Mao F, Cressman S, Traviglia S, Shao H, Hunter CL, Low DW, Cagle EN, Carnevali M, Guerigui V, Keogh PJ, Porter H, Stratton SM, Wiedeke MC, Wilken J, Tang J, Levy JJ, Miranda LP, Crnogorac MM, Kalbag S, Botti P, Schindler-Horvat J, Savatski L, Adamson JW, Kung A, Kent SB, Bradburne JA. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. *Science.* 2003; 299: 884–887.
26. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis stimulating agent for the treatment of anemia. *Curr Hematol Rep.* 2005; 4: 436–440.
27. Lippi G, Guidi G. Laboratory screening for erythropoietin abuse in sport: an emerging challenge. *Clin Chem Lab Med.* 2000; 38: 13–19.
28. Ashenden MJ, Sharpe K, Damsgaard R, Jarvis L. Standardization of reticulocyte values in an antidoping context. *Am J Clin Pathol.* 2004; 121: 816–825.
29. Sala C, Ciullo M, Lanzara C, Nutile T, Bione S, Massacane R, d'Adamo P, Gasparini P, Toniolo D, Camaschella C. Variation of hemoglobin levels in normal Italian populations from genetic isolates. *Haematologica.* 2008; 93: 1372–1375.
30. Engelmeyer E, deMarées M, Achtzehn S, Lundby C, Saltin B, Mester J. Inter- and intraindividual variations of Hb concentration with different interventions in elite cross country skiers. 12th Annual Congress of ECSS. 2007.
31. Malcovati L, Pascutto C, Cazzola M. Hematologic passport for athletes competing in endurance sports: a feasibility study. *Haematologica.* 2003; 88: 570–581.
32. Bechensteen AG, Lappin TR, Marsden J, Muggleston D, Cotes PM. Unreliability in immunoassays of erythropoietin: anomalous estimates with an assay kit. *Br J Haematol.* 1993; 83: 663–664.
33. Lindstedt G, Lundberg PA. Are current methods of measurement of erythropoietin (EPO) in human plasma or serum adequate for the diagnosis of polycythaemia vera and the assessment of EPO deficiency? *Scand J Clin Lab Invest.* 1998; 58: 441–458.

34. Marsden JT, Sherwood RA, Peters TJ. Evaluation of six erythropoietin kits. *Ann Clin Biochem.* 1999; 36 (Pt 3): 380–387.
35. Benson EW, Hardy R, Chaffin C, Robinson CA, Konrad RJ. New automated chemiluminescent assay for erythropoietin. *J Clin Lab Anal.* 2000; 14: 271–273.
36. Owen WE, Roberts WL. Performance characteristics of the IMMUNLITE 2000 erythropoietin assay. *Clin Chim Acta.* 2004; 340: 213–217.
37. Abellan R, Ventura R, Pichini S, Remacha AF, Pascual JA, Pacifici R, Di Giovannandrea R, Zuccaro P, Segura J. Evaluation of immunoassays for the measurement of erythropoietin (EPO) as an indirect biomarker of recombinant human EPO misuse in sport. *J Pharm Biomed Anal.* 2004; 35: 1169–1177.
38. Kuiper-Kramer EP, Huisman CM, van Raan J, van Eijk HG. Analytical and clinical implications of soluble transferrin receptors in serum. *Eur J Clin Chem Clin Biochem.* 1996; 34: 645–649.
39. Suominen P, Punnonen K, Rajamaki A, Irjala K. Evaluation of new immunoenzymometric assay for measuring soluble transferrin receptor to detect iron deficiency in anemic patients. *Clin Chem.* 1997; 43: 1641–1646.
40. Yeung GS, Kjarsgaard JC, Zlotkin SH. Disparity of serum transferrin receptor measurements among different assay methods. *Eur J Clin Nutr.* 1998; 52: 801–804.
41. Akesson A, Bjellerup P, Vahter M. Evaluation of kits for measurement of the soluble transferrin receptor. *Scand J Clin Lab Invest.* 1999; 59: 77–81.
42. Suominen P, Punnonen K, Rajamaki A, Majuri R, Hanninen V, Irjala K. Automated immunoturbidimetric method for measuring serum transferrin receptor. *Clin Chem.* 1999; 45: 1302–1305.
43. Cotton F, Thiry P, Boeynaems J. Measurement of soluble transferrin receptor by immunoturbidimetry and immunonephelometry. *Clin Biochem.* 2000; 33: 263–267.
44. Wians FH, Jr., Urban JE, Kroft SH, Keffer JH. Soluble transferrin receptor (sTfR) concentration quantified using two sTfR kits: analytical and clinical performance characteristics. *Clin Chim Acta.* 2001; 303: 75–81.
45. Paritpokee N, Bhokaisawan N, Wiwanitkit V, Boonchalermvichian C. Methodology evaluation of a new immunoturbidimetric method for measuring serum soluble transferrin receptor. *Asian Pac J Allergy Immunol.* 2001; 19: 207–211.
46. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. *Clin Chem.* 2002; 48: 1066–1076.
47. Abellan R, Ventura R, Pichini S, Sarda MP, Remacha AF, Pascual JA, Palmi I, Bacosi A, Pacifici R, Zuccaro P, Segura J. Evaluation of immunoassays for the measurement of soluble transferrin receptor as an indirect biomarker of recombinant human erythropoietin misuse in sport. *J Immunol Methods.* 2004; 295: 89–99.
48. Lippi G, Franchini M, Salvagno GL, Guidi GC. Biochemistry, physiology, and complications of blood doping: facts and speculation. *Crit Rev Clin Lab Sci.* 2006; 43: 349–391.
49. Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. *J Intern Med.* 1991; 229: 125–130.
50. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. *Nature.* 2000; 405: 635.
51. Zorzoli M. Recent advances in anti-doping settings. In: W. Schanzer, H. Geyer, A. Gotzmann, U. Marceck (eds) *Recent advances in doping analysis* (13). Sport und Buch Strauss, Köln. 2005; 255–264.
52. Harris EK. Effects of intra- and interindividual variation on the appropriate use of normal ranges. *Clin Chem.* 1974; 20: 1535–1542.
53. Ceriotti F, Hinzmann R, Panteghini M. Reference intervals: the way forward. *Ann Clin Biochem.* 2009; 46: 8–17.
54. Sottas PE, Robinson NE, Giraud S, Taroni F, Kamber M, Mangin P, Saugy M. Statistical classification of abnormal blood profiles in athletes. *Int J Biostatistics.* 2006; 2: 3.
55. Sottas PE, Robinson NE, Saugy M, Niggli O. A forensic approach to the interpretation of blood doping markers. *Law Probability and Risk.* 2008; 7: 191–210.
56. WADA. Athlete's Hematological Passport Blood Collection Protocol (to be released). www.wada-ama.org 2009.
57. WADA. Athlete's Hematological Passport Blood Storage and Transport Protocol (to be released). www.wada-ama.org 2009.
58. WADA. Athlete's Hematological Passport Blood Analytical Protocol (to be released). www.wada-ama.org 2009.
59. WADA. Athlete's Hematological Passport Interpretation Technical Document (to be released). www.wada-ama.org 2009.
60. Sottas PE, Saudan C, Schweizer C, Baume N, Mangin P, Saugy M. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. *Forensic Sci Int.* 2008; 174: 166–172.
61. Powrie JK, Bassett EE, Rosen T, Jorgensen JO, Napoli R, Sacca L, Christiansen JS, Bengtsson BA, Sonksen PH. Detection of growth hormone abuse in sport. *Growth Horm IGF Res.* 2007; 17: 220–226.
62. Erotokritou-Mulligan I, Bassett EE, Knies A, Sonksen PH, Holt RI. Validation of the growth hormone (GH)-dependent marker method of detecting GH abuse in sport through the use of independent data sets. *Growth Horm IGF Res.* 2007; 17: 416–423.

1. Kanstrup IL, Ekblom B. Blood volume and hemoglobin concentration as determinants of maximal aerobic power. *Med Sci Sports Exerc.* 1984; 16(3):256–262.
2. Gledhill N, Warburton D, Jamnik V. Haemoglobin, blood volume, cardiac function, and aerobic power. *Can J Appl Physiol.* 1999; 65–54:(1)24.
3. Craig NP, Norton KI, Bourdon PC, et al. Aerobic and anaerobic indices contributing to track endurance cycling performance. *Eur J Appl Physiol Occup Physiol.* 1993;67(2):150–158.
4. Wang MD, Yang M, Huzel N, Butler M. Erythropoietin production from CHO cells grown by continuous culture in a fluidized-bed bioreactor. *Biotechnol Bioeng.* 2002;77(2):194–203.
5. Choi D, Kim M, Park J. Erythropoietin: physico- and biochemical analysis. *J Chromatogr B Biomed Appl.* 1996;687(1):189–199.
6. Wide L, Bengtsson C, Berglund B, Ekblom B. Detection in blood and urine of recombinant erythropoietin administered to healthy men. *Med Sci Sports Exerc.* 1995; 27(11):1569–1576.
7. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. *Nature.* 2000; 405(6787):635.
8. Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. *Anal Biochem.* 2002;311(2):119–126.
9. Lasne F. Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. *J Immunol Methods.* 2003;276(1–2):223–226.
10. Wide L, Bengtsson C. Molecular charge heterogeneity of human serum erythropoietin. *Br J Haematol.* 1990;76(1):121–127.
11. Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. *Clin Chem.* 2002;48(11):2057–2059.
12. Breidbach A, Catlin DH, Green GA, Tregub I, Truong H, Gorzek J. Detection of recombinant human erythropoietin in urine by isoelectric focusing. *Clin Chem.* 2003;49(6 Pt 1):901–907.
13. WADA technical document TD2007EPO. 2007.
14. Lasne F, Martin L, Martin JA, de CJ. Isoelectric profiles of human erythropoietin are different in serum and urine. *Int J Biol Macromol.* 2007;41(3):354–357.
15. Lönnberg M, Drevin M, Carlsson J. Ultra-sensitive immunochromatographic assay for quantitative determination of erythropoietin. *J Immunol Methods.* 2008;339(2):236–244.
16. Franke WW, Heid H. Pitfalls, errors and risks of false-positive results in urinary EPO drug tests. *Clin Chim Acta.* 2006;373(1–2):189–190.
17. Kahn A, Baker M. Non-specific binding of monoclonal human erythropoietin antibody AE7A5 to *Escherichia coli* and *Saccharomyces cerevisiae* proteins. *Clin Chim Acta.* 2006; 379:173–175.
18. Beullens M, Delanghe JR, Bollen M. False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. *Blood.* 2006;107(12):4711–4713.
19. Khan A, Grinyer J, Truong ST, Breen EJ, Packer NH. New urinary EPO drug testing method using two-dimensional gel electrophoresis. *Clin Chim Acta.* 2005;358(1–2):119–130.
20. Rabin OP, Lasne F, Pascual JA, Saugy M, Delbeke FJ, Van EP. New urinary EPO drug testing method using two-dimensional gel electrophoresis. *Clin Chim Acta.* 2006; 373(1–2):186–187.
21. Reichel C. Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS. *J Mass Spectrom.* 2008;43(7):916–923.
22. Peltre G, Thormann W. Evaluation Report of the Urine EPO Test. Bern: Council of the World Anti-Doping Agency (WADA); 2003.
23. Lamon S, Robinson N, Sottas PE, et al. Possible origins of undetectable EPO in urine samples. *Clin Chim Acta.* 2007;385(1–2):61–66.
24. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. *Adv Chronic Kidney Dis.* 2009;16(2):117–130.
25. Barbone FP, Johnson DL, Farrell FX, et al. New epoetin molecules and novel therapeutic approaches. *Nephrol Dial Transplant.* 1999;14(Suppl 2):80–84.
26. Lamon S, Robinson N, Mangin P, Saugy M. Detection window of Darbepoetin-alpha following one single subcutaneous injection. *Clin Chim Acta.* 2007;379(1–2):145–149.
27. Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. *Curr Hematol Rep.* 2005; 4(6):436–440.
28. Wattendorf U, Merkle HP. PEGylation as a tool for the biomedical engineering of surface modified microparticles. *J Pharm Sci.* 2008; 97(11):4655–4669.
29. Macdougall IC. Recent advances in erythropoietic agents in renal anemia. *Semin Nephrol.* 2006;318–313:(4)26 .
30. Ashenden M, Varlet-Marie E, Lasne F, Audran M. The effects of microdose recombinant human erythropoietin regimens in athletes. *Haematologica.* 2006; 91(8):1143–1144.
31. Caldini A, Moneti G, Fanelli A, et al. Epoetin alpha, epoetin beta and darbepoetin alfa: twodimensional gel electrophoresis isoforms characterization and mass spectrometry analysis. *Proteomics.* 2003;3(6):937–941.
32. Kohler M, Ayotte C, Desharnais P, et al. Discrimination of recombinant and endogenous urinary erythropoietin by calculating

- relative mobility values from SDS gels. *Int J Sports Med.* 2008;29(1):1–6.
33. Reichel C, Kulovics R, Jordan V, Watzinger M, Geisendorfer T. SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. *Drug Test Anal.* 2009;1:43–50.
 34. Stubiger G, Marchetti M, Nagano M, Reichel C, Gmeiner G, Allmaier G. Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom.* 2005;19(5):728–742.
 35. Guan F, Uboh CE, Soma LR, et al. Differentiation and identification of recombinant human erythropoietin and darbepoetin Alfa in equine plasma by LC-MS/MS for doping control. *Anal Chem.* 2008;80(10):3811–3817.
 36. Guan F, Uboh CE, Soma LR, Birksz E, and Chen J. Identification of darbepoetin alfa in human plasma by liquid chromatography coupled to mass spectrometry for doping control. *Int J Sports Med.* 2009; 30(2):80–86.
 37. Groleau PE, Desharnais P, Cote L, Ayotte C. Low LC-MS/MS detection of glycopeptides released from pmol levels of recombinant erythropoietin using nanoflow HPLC-chip electrospray ionization. *J Mass Spectrom.* 2008; 43(7):924–935.